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Abstract
Therapeutic angiogenesis has emerged as a novel treatment approach for ischemic vascular
diseases. It relies on the delivery of exogenous growth factors to stimulate neovessel formation.
However, systemic administration of angiogenic factors results in rapid clearance from the site
of interest due to their short biological half-life. Mimicking the angiogenesis process is
multifaceted; therefore, therapeutic angiogenesis regimens should recapitulate both temporal
and spatial presentation of multiple growth factors. In this work, controlled delivery of two
growth factors, an angiogenic factor −fibroblast growth factor-2 (FGF2), and an arteriogenic
factor −fibroblast growth factor-9 (FGF9), from biodegradable poly(ester amide) (PEA)
electrospun fibers towards targeting neovascular formation and maturation, is reported.
FGF2 and FGF9 were dual loaded into PEA fibers using a mixed blend and emulsion
electrospinning technique. In vitro release kinetics of FGF2/FGF9 dual-loaded PEA fibers over
a period of 70 days showed controlled and concurrent release of both factors in a bioactive
form. Matrigel tube formation and Boyden chamber transwell assays conducted to evaluate
endothelial cell (EC) tube formation, directed smooth muscle cell (SMC) migration, and ECSMC interaction demonstrated that co-released FGF2 and FGF9 from dual loaded PEA fibers
enhanced EC tube formation (p < 0.05), directed-migration of SMCs towards PDGF-BB (p <
0.05), and EC/SMC tube stabilization. An ex ovo chick chorioallantoic membrane (CAM)
model coupled with power Doppler ultrasound imaging, and an in vivo ischemic hindlimb
mouse model were employed to assess the in vivo angiogenic capacity of the delivery system.
The CAM assay did not show a significant increase in the vascular density of the full CAM
surface treated with FGF2/FGF9 dual-loaded fibers (p > 0.05); however, the 3D power Doppler
volumes displayed enhanced localized angiogenesis underneath the fibrous mats with
enhanced blood perfusion and flow, as indicated by a statistically significant increase in
vascularization and vascularization flow indices for the dual-loaded PEA fibers group versus
the unloaded PEA fibers group (p < 0.05).
In order to evaluate the effectiveness of FGF9-loaded PEA fibers in vivo, an ischemic hindlimb
mouse model was used. Histological analysis of the ischemic tibialis anterior muscle revealed
increased percentage of mural cell-covered microvessels in mice treated with FGF9-loaded
PEA fibers than those treated with unloaded fibers. Interestingly, CatWalk gait analysis 7 days

post-ischemia did not demonstrate superior restoration of the ischemic hindlimb function for
the mice treated with FGF9-loaded PEA fibers, which might be too early for the healing of the
injured limb. Taken together, the data in this thesis supports the premise that controlled
delivery of fibroblast growth factors from biodegradable PEA electrospun fibers can provide
means for minimally invasive revascularization of ischemic tissues as a novel approach for
treatment of ischemic vascular diseases.

Keywords
Therapeutic angiogenesis; Controlled release; Angiogenic growth factors; Electrospun
poly(ester amide)s (PEAs) fibers; Fibroblast growth factor-2 (FGF2); Fibroblast growth factor-9
(FGF9).
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Chapter 1
1

Introduction
Overview

A functional vasculature transports oxygen, nutrients and signals to organs and tissues in
both healthy and diseased conditions. Ischemic vascular diseases including coronary heart
disease and peripheral arterial disease reduce blood flow and subsequently cause ischemia.
Considerable progress has been made in tackling cardiovascular disease in Canada over
the past 60 years with death rates declining by more than 75%. This resulted in 165,000
survivors in 2013; each one is a living proof on the importance of research in this area [1].
Despite this encouraging progress, there are 350,000 hospitalizations annually due to heart
disease and stroke in Canada. Each year approximately 70,000 heart attacks and 50,000
strokes send Canadians to emergency rooms [2]. Collectively, heart disease and stroke
costs the Canadian economy more than $20.9 billion every year in terms of physician
services, hospital costs, lost wages and decreased productivity [1, 3, 4].
Induction of neovessel formation (therapeutic angiogenesis) can offer a promising
approach to treat many ischemic vascular conditions, especially coronary and peripheral
arterial diseases [5]. Neovascularization can be achieved by three approaches: gene therapy
by promoting the expression of angiogenic genes, protein therapy by supplying angiogenic
growth factors, and cell therapy through delivering progenitor or stem cells. Protein
delivery is the most straightforward strategy and is considered as an ‘off-the-shelf’
treatment. However, systemic administration of the soluble angiogenic growth factors
results in their degradation and rapid clearance from the tissue of interest. Since neovessel
formation and tissue regeneration usually take from weeks to months [6], unlike bolus
delivery that provides a burst and short period of biological effects [5], controlled delivery
of the angiogenic factor over a long-term in a sustained manner is needed to protect its
bioactivity and prolong its therapeutic effects. Delivery vehicles for angiogenic factors can
be developed from natural or synthetic materials. Many natural materials have good
biocompatibility and degradability; however, they suffer from source and batch variations
that often lead to different biological properties. In addition, large-scale production of
1

natural materials is challenging. On the other hand, synthetic materials usually offer better
quality control. In view of this, the biomaterials field has sufficiently advanced to design
biocompatible and biodegradable materials with cell and tissue specificity.
The recent development of a new family of amino acid-based biodegradable poly(ester
amide)s (PEAs) that are susceptible to either hydrolytic or enzymatic degradation provides
additional resources to fabricate new biodegradable fibers with varying degradation rates
for potential biomedical applications, such as drug delivery and vascular tissue engineering
[7]. The by-products following degradation of these PEAs will include amino acids, which
are found physiologically, limiting their potential systemic toxicity [8, 9]. Moreover, their
degradation mechanism is governed by surface erosion [10], which limits the localized
accumulation of degradation by-products, supporting cell attachment and proliferation.
Unlike polyesters [11], PEA degradation is accompanied by the release of less acidic byproducts compared to polyesters, thus avoiding significant pH decrease in the vicinity of
the scaffold usually resulting in inflammatory responses. Furthermore, surface eroding
PEA scaffolds exhibit linear drug release kinetics, which provides better control of the drug
release profile. PEAs successfully synthesized in our laboratory were found to have the
potential to promote vascular tissue regeneration owing to their biomimetic properties and
favorable degradation profiles [8, 10]. Multiple growth factors can be loaded into PEA
delivery vehicles, potentially sustaining their release, enhancing their efficacy and
accelerating favorable cell-material interactions. In this work, PEA was used to fabricate
biodegradable electrospun fibers for dual and controlled delivery of angiogenic and
arteriogenic growth factors to support mature and functional neovessel formation.

Hypothesis and Objectives
1.2.1

Hypothesis

It is hypothesized that dual and controlled delivery of angiogenic and arteriogenic factors
from biodegradable electrospun PEA fibers promotes the assembly of stable and functional
neovasculature.
2

1.2.2

Objectives

In order to test the above hypothesis, the following objectives were formulated:
• Fabrication and optimization of PEA electrospun fibers, to obtain bead-free nanofibers
with uniform fiber diameter distribution and loading a model protein (bovine serum
albumin; BSA) and the target protein (fibroblast growth factor-9; FGF9).
• Dual loading of the PEA electrospun fibers with fibroblast growth factor-2 (FGF2) and
FGF9, and characterization of the delivery system in terms of morphological properties, in
vitro release kinetics, and bioactivity of the released growth factors.
• In vitro study of the effect of the growth factor-loaded PEA electrospun fibrous scaffold
on cell viability and proliferation using NIH-3T3 fibroblasts, 10T1/2 cells, and human
coronary artery smooth muscle cells (HCASMCs), inflammatory host response using
human monocytic cell line (THP-1), directed smooth muscle cell migration and endothelial
cell tube formation.
• In vivo angiogenesis evaluation of the developed PEA delivery system using an ex ovo
chick chorioallantoic membrane (CAM) model and ischemic hindlimb mouse model.

Thesis Outline
This thesis is divided into six chapters. A brief introduction about the clinical motivation
of this research (ischemic vascular disease) and the need for new treatment approaches
such as therapeutic angiogenesis, together with the hypothesis and objectives are
introduced in Chapter 1. A broad literature review of recent advances in growth factor
delivery for therapeutic angiogenesis is presented in Chapter 2. The main research findings
are presented in Chapters 3-5. Chapter 3 reports the fabrication and optimization of PEA
electrospun fibers and loading them with a model protein (BSA) and FGF9 using either
blend or emulsion electrospinning technique and their characterization in terms of
3

morphological properties, in vitro release kinetics, and bioactivity of the released growth
factor. Chapter 4 discusses dual loading of the PEA electrospun fibers with FGF9 and
FGF2 using a mixed blend and emulsion electrospinning technique, in vitro angiogenesis
assays and evaluating the inflammatory host response using THP-1 human monocytes.
Chapter 5 focuses on the in vivo angiogenesis evaluation of the FGF-loaded PEA fibers
using ex ovo chick choriallantoic membrane model and ischemic hindlimb mouse model.
Finally, a general discussion with conclusions outlining the strengths, limitations and
future directions are presented in Chapter 6.
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Chapter 2
2
Literature Review: Advances in Growth Factor Delivery for
Therapeutic Angiogenesis
Overview: This chapter provides background information on natural blood vessel
formation, signaling molecules involved in the angiogenesis process, angiogenic growth
factor delivery; highlighting the benefits of their controlled delivery and spatiotemporal
presentation, and lastly discussing safety concerns of the angiogenic growth factor
delivery.

Abstract
Therapeutic angiogenesis is a new revascularization strategy to induce new vessel
formation. The biology and delivery of angiogenic growth factors involved in vessel
formation have been extensively studied but success in translating the angiogenic capacity
of growth factors into benefits for vascular disease patients is still limited. This could be
attributed to issues related to patient selection, growth factor delivery methods or lack of
vessel maturation. Comprehensive understanding of the cellular and molecular cross-talk
during the different stages of vascular development is needed for the design of efficient
therapeutic strategies. The presentation of angiogenic factors either in series or in parallel
using a strategy that mimics physiological events, such as concentration and spatiotemporal profiles, is an immediate requirement for functional blood vessel formation. This
review provides an overview of the recent delivery strategies of angiogenic factors, and
discusses targeting neovascular maturation as a promising approach to induce stable and
functional vessels for therapeutic angiogenesis.
Key words: Growth factors; Neovascular maturation; Therapeutic angiogenesis.

*

A version of this chapter is published as a review article “Somiraa S. Said, J. Geoffrey Pickering and
Kibret Mequanint, Journal of Vascular Research (2013), 50; 35-51”. Adapted with permission from
KARGER Publishers © 2012.
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Introduction
Notwithstanding rapid advances made in treatment options, cardiovascular diseases
remained the leading cause of death in developed countries [1] . In 2008, ischemic heart
disease accounted for 7.3 million deaths worldwide [2]. The primary cause of ischemic
heart disease is atherosclerosis - a thickening of the lining of the coronary arteries, and the
subsequent myocardial ischemia - resulting in functional deficits and infarction. Although
considerable progress has been made in preventing and treating atherosclerotic vascular
disease (such as thrombolysis, angioplasty, stenting, and surgical bypass), there is no better
clinical alternative to the patient's own blood vessels when a coronary artery must be
bypassed. However, autologous vein and artery grafts cannot always be used either due to
damage, pre-existing disease, or distal coronary arteries that are unsuitable for surgical
anastomosis. On the other hand, synthetic grafts can result in immunologic and thrombotic
complications [3]. Consequently, nearly 7% of ischemic heart disease patients become
ineligible for standard revascularization techniques such as angioplasty or bypass surgery
[4]. In these patients, the challenge to improve blood flow to the ischemic heart has led to
extensive research and numerous innovative approaches in the field of vascular
regenerative medicine [5]. One of the novel strategies in vascular regenerative medicine is
therapeutic angiogenesis, which can include the administration of growth factors to induce
new vessel formation. This technique has been shown to promote myocardial healing after
an infarct in animals demonstrating the functional importance of augmenting the coronary
circulation [6, 7]. This, in turn, accelerates the potential of therapeutic angiogenesis as a
treatment modality to patients with advanced symptomatic ischemic heart disease, who are
ineligible to receive standard invasive revascularization strategies [8, 9]. In this review, an
overview of the biology of angiogenesis is provided along with the discussion of the basic
characteristics of angiogenic factors, different delivery technologies, and neovascular
maturation to form stable and functional vessels through therapeutic angiogenesis
strategies.
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Blood Vessel Formation: Vasculogenesis, Angiogenesis and
Arteriogenesis
Coronary vasculogenesis, arteriogenesis, and angiogenesis are a spectrum of processes that
lead to vessel formation [10]. Vasculogenesis is the de novo formation of blood vessels in
the embryo from angioblasts or endothelial progenitor cells that migrate, proliferate, and
differentiate to form endothelial cells (ECs), and subsequently organize into cord-like
structures [11, 12]. It involves

both cell-cell and cell-extracellular matrix (ECM)

interactions directed spatially and temporally by growth factors [13]. This dynamic process
has also been recently suggested to occur in adulthood, where circulating endothelial
progenitor cells are recruited to ischemic sites [14]. Arteriolar networks are often
remodeled postnatally by the maturation of pre-existing collaterals in response to metabolic
demands through the process of arteriogenesis [15]. Angiogenesis, on the other hand, is the
process of blood vessel sprouting from pre-existing vasculature and includes subsequent
remodeling steps such as pruning, vessel enlargement, and intussusceptions to form stable
vessel networks [16, 17]. Angiogenesis is a beneficial process occurring naturally during
wound healing, the female monthly reproductive cycle, and pregnancy. Alternatively,
angiogenesis can occur as a part of a diseased body where it can aid in cases of ischemia
or lead to a disease in the promotion of tumors [18]. During normal function, the body
controls the growth of blood vessels using pro-angiogenic factors to stimulate and antiangiogenic factors to negatively regulate this phenomenon. The events of the angiogenesis
process occur in an orderly series (Figure 2-1). It starts by the release of angiogenic growth
factors from the ischemic tissues, diffusing into the nearby tissues. The angiogenic growth
factors then bind to specific receptors located on the ECs of nearby pre-existing blood
vessels. Once growth factors bind to their receptors, the ECs become activated, sending
signals from the cells' surface to the nucleus. The EC machinery begins to produce new
molecules including enzymes that degrade the basement membrane surrounding existing
vessels. ECs begin to proliferate and migrate out and integrins facilitate sprouting of the
new blood vessel forward. Additionally matrix metalloproteinases are produced to degrade
the ECM in the direction of the sprouting vessel tip in order to accommodate it. As the new
vessel extends, the tissue is remodeled around the vessel. Subsequent to this, sprouting ECs
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roll up to form a tube. Individual tubes connect to form blood vessels that can circulate
blood. Newly formed blood vessel tubes are stabilized by specialized perivascular cells,
referred to as mural cells, which can be either vascular smooth muscle cells (VSMCs) or
pericytes. Pericytes are thought to stabilize capillaries, whereas VSMCs are critical for the
control of vessel conductance which is required for the restoration of blood flow [18]. With
continuing flow as well as increasing shear stress and blood pressure over time during
vascular development, greater vessel stability is required. Such vessel stability is attained
through EC-mural cell interactions and concomitant ECM remodeling including deposition
and cross-linking of ECM components (i.e., basement membranes, interstitial matrices, and
elastin-rich matrices) at distinct places in the vessel wall [19, 20].

Figure 2-1: Major events of the angiogenesis process.
(A) Angiogenic factor production and release to the surrounding tissue. (B) Paracrine
signalling via angiogenic factor-EC receptor binding. (C) Endothelial cell directional
migration and tube elongation. (D) Nascent vessel branching. (E) Neovascular maturation
and investment of perivascular cells. Modified from the Angiogenesis foundation website
[18].
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In view of the above, the goal of therapeutic angiogenesis is to enhance the natural process
of ischemic revascularization through delivery of angiogenic factors, and to increase blood
vessel density and tissue function [3]. Understanding the molecular mechanisms of
vascular maturation is essential in developing competent neovascularization strategies. For
such complicated developmental process, multiple angiogenic factors are required that act
synchronically to form the correct patterning found within a functional blood vessel [3].

Angiogenic Growth Factors
Ischemia resulting from an arterial occlusion is a natural stimulus for endogenous
angiogenesis which induces upregulation of angiogenic growth factors and mobilization of
circulating cellular elements collectively enabling the development of an accessory
vasculature [5, 21]. In the sections that follow, major angiogenic growth factors are
outlined whereas additional factors are listed in Table 2-1.
Table 2-1: Selected signaling molecules involved in angiogenesis process [22].
Signaling molecule

Function(s)
Involved in angiogenesis and lymphangiogenesis, act

Vascular endothelial growth

specifically on ECs to induce their migration, proliferation,

factors

formation of new blood vessels, and induce vascular
permeability
Involved in angiogenesis, EC proliferation, cord and lumen

Fibroblast growth factors

formation, recruitment of inflammatory cells, pericytes and
VSMCs, and vessel maturation
Promote vascular maturation by recruiting VSMCs and

Platelet-derived growth
factors

pericytes to newly formed vessels, induce inflammatory cell
chemotaxis, recruit stem cells from bone marrow, and
responsible for the migration of SMC and formation of the
neointima
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EC chemotaxis, prevention of excessive vascular
Angiopoietin-1

permeability, formation of cords and lumens, and vessel
stabilization via EC-mural cells interactions

Angiopoietin-2

Nitric oxide

Vessel destabilization, detachment of VSMCs, and
degradation of ECM
Vasodilatation, co-factor for VEGFs, FGFs and other
angiogenic factors
Mobilization of bone marrow–derived stem cells, induces

Granulocyte colony-

proliferation and enhance survival of cardiomyocytes by direct

stimulating

effects on cardiomyocytes, or by the release of proangiogenic

factor

mediators
Upregulation of several genes to promote survival in low-

Hypoxia-inducible factor 1a

oxygen conditions. These include glycolysis enzymes, which
allow ATP synthesis in an oxygen-independent manner, and
VEGF, which promotes angiogenesis
It is secreted by mesenchymal cells and acts as a multifunctional cytokine on cells of mainly epithelial origin. Its

Hepatocyte growth factor

ability to stimulate mitogenesis, cell motility, and matrix
invasion gives it a chief role in angiogenesis and tissue
regeneration
A key regulator of cellular proliferation and differentiation,

Insulin-like growth factor

promotes physiological cardiac growth, reduces apoptosis and
collagen deposition, enhances angiogenesis, and improves
cardiac function

2.4.1

Vascular Endothelial Growth Factor (VEGF) Family

Among the many factors implicated in angiogenesis, VEGF is one of the most investigated
families of angiogenic growth factors. The VEGF family includes VEGF-A, -B, -C, -D, 11

E, -F and placental growth factor (PlGF). VEGF-A is mainly involved in angiogenesis
while VEGF-C and VEGF-D are involved in lymphangiogenesis. The human VEGF-A
gene is organized into eight exons and alternative exon splicing results in 5 different
isoforms (VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206) [23-25]. VEGF165 is the
most predominant isoform as well as the most potent in terms of stimulating angiogenesis
[3]. VEGF ligands mediate their angiogenic effects by binding to specific VEGF receptors,
leading to receptor dimerization and downstream signal transduction. VEGF receptor
signalling is detailed elsewhere and the reader is referred to excellent reviews on this
subject [26, 27]. VEGF ligands bind to 3 primary receptors (VEGFR-1, VEGFR-2 and
VEGFR-3) and 2 co-receptors (neuropilin receptors NP-1 and NP-2). Of the primary
receptors, VEGFR-1 and VEGFR-2 are mainly associated with angiogenesis [28]. The
third primary receptor, VEGFR-3, is associated with lymphangiogenesis. Endothelial
expression of VEGF receptors varies among the 3 primary receptors; VEGFR-2 is
expressed on almost all ECs, while VEGFR-1 and -3 are selectively expressed in distinct
vascular beds [5]. VEGF acts specifically on ECs to induce their migration, proliferation,
and formation of new or large vessels [3]. It also can act in an autocrine manner and
increases vascular permeability. VEGF induces vascular permeability, vasodilatation, and
upregulates expression of serinoproteases and interstitial collagenases, thereby promoting
ECM degradation [29, 30]. VEGF production and subsequent angiogenesis can be
triggered by a number of factors in the cellular microenvironment including but not limited
to hypoxia, oncogenes, tumor suppressor genes, inflammatory cytokines, and other growth
factors [31]. For example, acute myocardial infarction rapidly produces a prolonged overexpression of VEGF and its receptors [32]. Moreover, it has been documented that VEGF
increases the number of circulating endothelial progenitor cells in humans after VEGF gene
therapy [33].

2.4.2

Fibroblast growth factor (FGF) family

FGFs are another large family of growth factors directly involved in angiogenesis [34].
FGFs are pleiotropic factors that can stimulate and act on different cell types, including
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vascular ECs. The FGF gene family is composed of 22 members that bind to seven FGF
receptor isoforms (FGFR1b, FGFR1c, FGFR2b, FGFR2c, FGFR3b, FGFR3c and FGFR4) [35].
The bulk of angiogenic experimental data is focused on FGF-1 (acidic, aFGF) and FGF-2
(basic, bFGF) both of which are potent EC mitogens that also serve as ligands for other
cell types, including VSMCs and fibroblasts. FGF binding induces receptor tyrosine kinase
(RTK) dimerization, which leads to the activation of signalling pathways involved in cell
growth, differentiation, tissue maintenance, and wound repair [35]. FGF induces
neovascularisation in vivo and is implicated in the growth of new blood vessels during
wound healing and embryogenesis. In vitro, FGF induces cell proliferation, migration, and
production of proteases in ECs by interacting with specific co-receptor systems consisting
of tyrosine kinase FGF receptors (FGFRs) and heparin-like glycosaminoglycans (HLGAG)
[5, 36]. It has been reported that FGFs act through autocrine, intracrine or paracrine
mechanisms to induce angiogenesis in vascular lesions [37]. Although intimate cross-talk
takes place between the FGF-2 and VEGF signalling pathways often activating one another
to promote angiogenesis, these growth factors, however, have distinct biological effects on
ECs [3, 37].

2.4.3

Platelet-derived Growth Factor (PDGF)

PDGF is a pluripotent angiogenic growth factor synthesized by many different cell types
in response to external stimuli such as hypoxia or growth factor stimulation, and it has a
broad expression pattern [3]. PDGF, together with other growth factors, such as VEGF and
FGF, promotes vascular maturation by recruiting VSMCs and pericytes to newly formed
vessels [38, 39]. In addition, PDGF mediates collagen production by fibroblasts, regulates
lymphatic growth, induces inflammatory cell chemotaxis and recruits stem cells from bone
marrow [40].
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2.4.4

Other Angiogenic Stimulators

The presence of inflammatory cells like macrophages, monocytes and neutrophils triggers
an angiogenic response [29]. In addition to the angiogenic factors discussed in the
preceding sections, several other growth factors that impact angiogenesis such as
angiopoietins (Ang-1 and Ang-2), monocyte chemotactic protein-1 (MCP-1), granulocyte
macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), leptin,
transforming growth factors (TGF-α and TGF-β), tumour necrosis factor alpha (TNF-α),
and brain-derived neurotrophic factor (BDNF) have been identified [5]. Furthermore nonpeptide molecules, such as nitric oxide (NO), prostaglandins, adenosine and hyaluronic
acid have been also reported to have pro-angiogenic properties [29]. However, clinical
trials have focused mostly on members of the VEGF and FGF families [6, 8]. Table 2-1
summarizes the role of selected signalling molecules involved in the angiogenic process.

Angiogenic Growth Factor Delivery
2.5.1

Protein versus Gene Therapy

Therapeutic angiogenesis regimens have focused on the administration of a single growth
factor, in spite of the complexity of the angiogegenesis process, with VEGF-A and FGF 1
and 2 being the most extensively studied angiogenic factors [22]. Growth factor proteins
can be administered either directly or via gene-based approaches, employing naked
plasmid DNA or a viral vector that encodes the gene to be incorporated by the host ECs
[22]. Obvious advantages of gene therapy strategy include longer-term expression of an
angiogenic gene and targeting a specific tissue. However, the local concentration of the
angiogenic protein is highly dependent on the level of expression of its gene, which is
difficult to regulate [41]. Safety concerns usually exist regarding the exposure of patients
to foreign genetic material and viral vectors. As well, the effectiveness of gene transfection
methods can be compromised by preformed antibodies and inflammatory responses, and
the probability of inactivation could increase with re-administration. Protein therapy may
arguably be more applicable for clinical use than gene therapy, due to the more predictable
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initial dosing of the angiogenic factor, pharmacokinetics and tissue therapeutic levels.
Additionally, the use of controlled-release delivery systems can provide prolonged
exposure, compensate for the short biological half-life of the angiogenic growth factors,
and avoid potential adverse effects of the high plasma concentrations, which is required for
adequate myocardial uptake [22]. However, recombinant proteins can be difficult and
expensive to produce and may require complicated delivery technologies.

2.5.2

Gene Transfer in Therapeutic Angiogenesis

Early studies of gene therapy utilized plasmid DNA owing to its safety and ease of
production. Despite the promising results of VEGF encoding plasmid DNA and other
angiogenic factors in preclinical trials and small clinical trials [42, 43], large randomized
controlled trials did not support the use of plasmid DNA, due to its low transduction
efficacy, lack of a dose response effect, and its transient expression [44, 45]. Although,
plasmid DNA is considered safe, it can result in transient fever, inflammation, and
sometimes myocardial infarction [44, 46]. Adenovirus (Ad) vectors have demonstrated
high transduction efficacy, and more specifically, they are much more efficient than
plasmid DNA in the myocardium [47]. Retroviruses were the first vectors to be used for in
vivo cardiovascular gene transfer, but safety concerns led to reduced interest in them [48].
As an alternative strategy, lentiviruses have been recently used in cardiovascular gene
therapy, for the treatment of familial hypercholesterolemia [49], whereas sendai viruses
[50] and herpesviruses [51] have also been utilized in some cardiovascular gene therapy
applications. Finally, baculoviruses were found to transduce blood vessels transiently with
a moderate efficiency [52]. Despite this encouraging data, their advantage is not clear as
macrophage-specific immunostaining detected signs of inflammation comparable to
adenoviruses.
Adeno-associated virus (AAV) vectors are attractive candidates for cardiovascular gene
therapy having a natural tropism towards VSMCs, cardiomyocytes and skeletal muscles.
AAV transduces quiescent cells, and drives long-term gene expression lasting several
months. It generates only a restricted inflammatory reaction, and the wild-type virus is not
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known to cause any diseases in humans [53]. AAV has a long-lasting gene expression
pattern with lower maximal gene expression levels than those induced by Ads [54]. Most
importantly, the peak expression of AAVs can be achieved in just a few days after the
transduction [55].

Preclinical Studies
2.6.1

In vivo Studies with Vascular Endothelial Growth Factor

Animal studies with VEGF have mainly involved VEGF165 and VEGF121 isoforms. There
have been successful results in myocardial ischemia models [56-59]. In one study, the
implantation of collagen membrane patch loaded with collagen-binding domain fused to
VEGF into infarcted rabbit myocardium, effectively improved left ventricle cardiac
function and increased vascular density compared to control group [57]. In a rat model of
a resected right ventricular free wall and replaced with the VEGF-immobilized collagen
scaffold, Miyagi et al. [58] reported that covalently immobilized VEGF-collagen scaffolds
improved tissue formation, increased blood vessel density and reduced construct thinning.
Controlled delivery of VEGF165 from poly(lactic-co-glycolic acid) (PLGA) microparticles
in a rat model of myocardial ischemia-reperfusion, resulted in enhanced angiogenesis and
arteriogenesis after one month of the treatment [56]. Sustained and localized delivery of
VEGF together with insulin-like growth factor-1 from biodegradable gelatin microspheres
was proved to attenuate post-myocardial infarction remodeling in a rat model of
experimental heart failure [59]. Also, gene transfer of adenoviral VEGF-A165 and the
mature form of VEGF-D, injected intramyocardially into pigs via a catheter-mediated
approach, resulted in transmural angiogenesis induction in porcine heart [60].

2.6.2

In vivo Studies with Fibroblast Growth Factor

FGF-1 and FGF-2 have been the most studied of the FGF family. FGF-1 plays a pivotal
role in the spontaneous formation of collaterals as it is strongly expressed in ischemic
myocardium [22, 61]. Large animal studies using FGF-1 to stimulate angiogenesis initially
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produced disappointing results, which can be argued by the short biological half-life (15
minutes at 37°C) of the FGF-1 [62]. Intramyocardial sustained delivery of FGF2−impregnated gelatin hydrogel microspheres was demonstrated to enhance angiogenesis
and ventricular function in a rat myocardial infarcted heart model [63]. Improved
myocardial perfusion and cardiac function by controlled-release of FGF-2 using fibrin
glue, was reported in a canine acute infarct model - induced by ligation of the left anterior
descending coronary artery - with dramatic increase of the total vascular density in
comparison with the control group that underwent coronary artery ligation without
treatment [64]. In another study, heart failure due to myocardial infarction was induced in
pigs followed by intramyocardial administration of biodegradable gelatin microspheres
loaded with bFGF 4 weeks after infarction, which resulted in improved left ventricular
(LV) function and inhibited LV remodeling compared to the control group [65]. In a
preclinical study using a pig model of myocardial ischemia, a single intracoronary infusion
of adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4), improved cardiac contractile
function and regional blood flow in the ischemic region during stress [66].

Clinical Trials in Ischemic Heart Disease
After preclinical studies had established a proof of concept for therapeutic angiogenesis,
investigators sought to extrapolate these findings to patients with myocardial ischemia.
Patients included in the clinical trials of therapeutic myocardial angiogenesis, suffered
from severe angina unresponsive to medical therapy and were unsuitable for standard
revascularization techniques [5]. Major therapeutic angiogenesis clinical trials for
myocardial ischemia using protein/gene therapy are summarised in Table 2-2.
Most of these clinical trials showed little success in translating the angiogenic capacity of
growth factors into benefits to ischemic heart disease patients either through gene or protein
therapy. The potential reasons for such poor results include the limited duration of the
therapy achieved with bolus delivery of recombinant proteins or gene delivery vectors, the
high costs associated with protein therapy because of the need for large doses and
complicated delivery technologies, issues with patient selection, and the generation of
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immature and unstable blood vessels that regress over time. Potential strategies to
overcome these challenges include the use of controlled delivery systems that allow
prolonged angiogenic stimulation and the use of growth factor combinations to stimulate
the generation of mature and stable blood vessels. Ultimately, the key is acquiring a
neovasculature that can effectively deliver flow via vasoresponsiveness - the dynamic
regulation of the luminal diameter of arterioles, which is crucial for controlling the
metabolic needs of the tissues.
Table 2-2: Major randomized myocardial angiogenesis clinical trials using
protein/gene therapy.
Growth factor

Route and dose

n

Results

Reference

Granulocyte-

40 µg intracoronary

21

Short-term administration protocol of

Seiler et al.

macrophage

(IC) once and 10

GM-CSF showed significant

[67]

colony

µg/kg subcutaneous

improvement of collateral flow index

stimulating

(SC) for 2 weeks

(p < 0.05) and ECG signs (p = 0.04)
after vascular balloon occlusion.

factor (GMCSF)
GM-CSF

10 µg/kg SC for 2

14

weeks

Subcutaneous short-term protocol of

Zbinden et

GM-CSF significantly promotes

al. [68]

coronary collateral artery growth
among patients with CAD. However,
two cases of acute coronary
syndromes in the treatment group
were reported.
Granulocyte

10 µg/kg SC for 5 d

colony

114

Stem cell mobilization by G-CSF

Zohlnhofer

after percutaneous

therapy in patients with acute

et al. [69]

stimulating

coronary intervention

myocardial infarction had no

factor (G-

(PCI) for acute

significant influence on infarct size,

CSF)

myocardial infarction

left ventricular function, or coronary

(AMI)

restenosis.
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G-CSF

10 µg/kg SC for 6

78

Bone marrow stem cell mobilization

Ripa et al.

days after PCI for

with subcutaneous G-CSF did not

[70]

AMI

lead to significant improvement in
ventricular function after acute
myocardial infarction.

FGF-2

10 or 100 µg

24

Magnetic resonance assessment of the

Laham et al.

delivered via

target ischemic zone showed

[71]

sustained-release

significant improvement of

heparin-alginate

myocardial perfusion and reduction in

microcapsules

the target ischemic area in the 100 µg

implanted in

bFGF group, 3 months after CABG.

ischemic myocardial
territories during
coronary artery
bypass graft (CABG)
Recombinant

0, 0.3, 3, 30 µg/kg IC

337

FGF-2

A single IC infusion of rFGF-2

Simons et al.

showed no significant difference of

[72]

exercise tolerance or myocardial
perfusion. But does show trends
toward symptomatic improvement at
90 days but not at 180 days due to the
continued improvement in the
placebo group.
A trend towards clinical improvement

Grines et al.

GF-4

in exercise treadmill testing. Single

[73]

(Ad5FGF-5)

intracoronary administration of Ad5-

Adenovirus5F

5 ascending doses IC

79

FGF4 was safe and well tolerated
with no immediate adverse events.
Recombinant

17 ng/kg/min IC and

VEGF-A165

intravenous (IV) or

178

19

rhVEGF offered no improvement

Henry et al.

beyond placebo in all measurements

[74]

50 ng/kg/min IC and

by Day 60. High-dose rhVEGF

IV

resulted in significant improvement in
angina class and non-significant
improvement in exercise tolerance
time and angina frequency at 120
days compared to placebo.

AdVEGF165 or

(2 × 1010 pfu or 2 mg

naked plasmid

AdVEGF121

Significant improvement of

Hedman et

DNA) IC during

myocardial perfusion in the

al. [44]

percutaneous

adenoviral VEGF group at 6 months.

transluminal

No difference in vessel restenosis

coronary angioplasty

rates.

2 × 1010 pfu

103

67

intramyocardial

Improvement in exercise-induced

Stewart et al.

ischemia at 26 weeks.

[75]

No significant improvement of stress-

Kastrup et al.
[45]

injection via minithoracotomy
Naked

0.5 mg percutaneous

80

VEGF165

intramyocardial

induced myocardial perfusion.

plasmid

injection

However, regional wall motion was
significantly improved.

Plasmid

2.0 mg

VEGF165

93

No improvement in myocardial

Stewart et al.

intramyocardial

perfusion; significant reduction in the

[76]

injection

ischemic area, increase in exercise
test time and improvement in angina
class.

AdGV-

intramyocardial

VEGF121

injection

17

No significant difference in

Kastrup et al.

myocardial perfusion and exercise

[77]

capacity at 52 weeks. Premature study
termination.
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Targeting Neovascular Maturation
2.8.1

Cues for Functional Blood Vessel Formation

Pericyte and VSMC recruitment to nascent vessels is pivotal for vessel maturation [78].
Absence of perivascular cell coverage subjects newly formed vessels to regression and they
become dependent upon ongoing growth factor stimulation from the environment for their
survival [79]. However, nascent vessels are stabilized and become resistant to regression
once they are invested with pericytes. Basement membrane matrices are one of the key
ECM components facilitating EC tube stabilization. They are in direct contact with the ECs
layer on its abluminal surface and provide important signals that control the stability of this
layer. Despite the substantial information which exists on the signalling properties of
basement membrane components toward different cell types, much remains to be learned
concerning how such components affect EC behaviour at distinct stages of vascular
morphogenesis and stabilization in embryonic and postnatal life [80]. The importance of
pericyte recruitment to EC-lined tubes in vitro and in vivo, has been demonstrated to be
essential to stimulate vascular basement membrane matrix assembly, which is considered
a key step in vascular maturation and stabilization [81]. Not surprisingly, stimulation of
cell migration for vascular maturation is growth factor dependent. This is exemplified by
Regranex®, a genetically engineered PDGF based commercial product developed for the
recruitment of cells in wound healing [82]. Although its reported mechanism of action is
through mesenchymal cell proliferation and matrix production, there is a probability that
part of PDGF’s mechanism of action in chronic wound healing may also be due to
improvement of neovascular maturation [83].
The endothelial basement membrane is unique in its accumulation of the protein von
Willebrand Factor (vWF), which is derived from endothelial Weibel-Palade body
secretions [84]. Following the formation of a quiescent vasculature, vWF plays an essential
role in haemostasis. In addition to its role in the recruitment, adhesion, and migration of
leukocytes, vWF has been recently shown to play a role in vessel patterning [85]. Although
multiple cell types, secreted proteins, and growth factors collectively and in coordination
regulate angiogenesis and vessel stabilization, the Notch signalling pathway is unique in
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its involvement in multiple stages of angiogenesis, from initial vascular plexus formation
and patterning, to VSMC recruitment and vascular remodeling [86]. Scheppke et al. [86]
reported that VSMC recognition of the Notch ligand (Jagged1) on ECs leads to expression
of integrin αvβ3 on VSMCs. Once expressed, integrin αvβ3 facilitates VSMC adhesion to
vWF in the endothelial basement membrane of developing retinal arteries, leading to vessel
maturation. Their conclusions were based on the notion that genetic or pharmacological
disruption of Jagged1, Notch, αvβ3, or vWF suppresses VSMC coverage of nascent vessels
and arterial maturation during vascular development [86].

2.8.2

Co-delivery of Ang-1, PDGF-BB, or HGF with VEGF and FGF-2 for

Vascular Stabilization
Given the lack of clear benefits of VEGF gene therapy in two major clinical trials [45, 76],
targeting neovascular maturation is an attractive alternative or supplementary strategy to
ensure efficient therapeutic angiogenesis. Although, VEGF directly stimulates EC
proliferation and migration, it has been reported that it can act as an inhibitor of
neovascularization on the basis of its capacity to disrupt VSMC function [87]. Specifically,
under conditions of PDGF-mediated angiogenesis, VEGF ablates pericyte coverage of
nascent vascular sprouts, leading to vessel destabilization [87]. Perivascular nascent vessel
maturation process is a natural feature of blood vessel development in the embryo [88];
however, there are no strategies for promoting an equivalent vascular maturation process
in ischemic adult tissues. Such strategies could also be important to the viability of tissueengineered substitutes, which can be compromised by inefficient vascularization and
oxygen delivery [89]. Evidently, the formation of a mature vasculature requires precise
spatial and temporal regulation of a large number of angiogenic stimulators and inhibitors.
The complexity and heterogeneity of the factors involved in vascular maturation suggest
the use of a co-delivery or sequential delivery approach, to overcome the drawbacks of
single growth factor delivery. For example, systemic co-administration of Ang-1 and
VEGF through intravenous adenoviral delivery has been shown to protect adult vasculature
from lethal vascular leakage induced by systemic VEGF expression [90]. Local coexpression of VEGF and Ang-1 has been reported to reduce VEGF-induced leakage in rat
22

hind limb ischemia [91]. Temporally separated delivery of VEGF and Ang-1 gene therapy
also resulted in sustained and functional neovascularization in unilateral hind limb
ischemia rat model [92]. Moreover, adenoviral delivery of VEGF and Ang-1 induced
vessels that were more mature and persisted after 4 weeks compared to VEGF alone [93].
Adeno-associated viral vectors expressing cardiac-specific and hypoxia-inducible VEGF
[AAV-myosin light chain-2v (MLC)VEGF] and Ang1 (AAV-MLCAng1) were co-injected
in a porcine myocardial infarcted heart model [94]. Cardiac–specific and hypoxia–induced
co-expression of VEGF and Ang1 was found to improve the perfusion and function of
porcine myocardial infarcted heart through the induction of angiogenesis and
cardiomyocyte proliferation [94].
Similarly the approach of co-delivering PDGF-BB with VEGF is justified by the
suggestion that increasing the recruitment of pericytes could provide a comprehensive
stimulation of several pathways in a co-ordinated fashion, and hence better simulation of
the physiological process. Delivery of recombinant VEGF and PDGF-BB proteins from a
PLGA scaffold has been shown to induce larger and more mature vessels compared with
VEGF alone subcutaneously and in ischemic skeletal muscle [95]. The combination of
recombinant PDGF-BB with FGF-2 has been reported to increase vascular stabilization in
the mouse cornea and in rat and rabbit hind limb ischemia models [38]. However, the codelivery of PDGF-BB was found not to correct VEGF induced abnormalities in the cornea.
Thus, it was not pursued further in the more clinically relevant muscular tissue. Co-delivery
of the VEGF and PDGF-BB genes to ischemic myocardium by venous retroinfusion of
adeno-associated viral vector has recently been found to significantly improve perfusion
and collateral arteriogenesis [96]. It is worth mentioning that PDGF together with other
factors, originating from the aggregating platelets, mononuclear cells, endothelial cells, and
VSMCs themselves at the site of injury, act as a proliferating agent and are responsible for
the migration of the VSMCs and the process of restenosis [97]. Given the beneficial effect
of VEGF and PDGF co-delivery in prior studies [38, 95], the suggestion that PDGF causes
restenosis requires further investigation.
In addition to Ang-1 and PDGF-BB, co-delivery of HGF was reported to potently induce
arteriogenesis and reduce cardiac fibrosis. Intramyocardial delivery of cross-linked
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albumin-alginate microcapsules that sequentially release FGF-2 and HGF was investigated
in a rat model with chronic heart failure induced by coronary ligation [98]. Data from the
study indicated that dual delivery stimulated angiogenesis and prevented cardiac
hypertrophy and fibrosis, leading to improved cardiac perfusion after 3 months.

2.8.3

Acquiring Neovasculature Vasoresponsiveness

Although stimulating angiogenesis using growth factors is an essential first step, it is not a
sufficient condition for its efficiency. It has become recognized that angiogenic growth
factors cannot generate vasoreactive neovessels by themselves [99]. Vasoreactivity is the
dynamic regulation of the luminal diameter of arterioles and arteries and it is vital to
controlling flow into capillary beds, and consequently, to meeting the oxygen and
metabolic needs of tissues. Frontini et al. [99] reported that the delivery of fibroblast
growth factor-9 (FGF-9) imparts stability, longevity and the ability to regulate blood flow
through vasoresponsiveness of the newly formed microvessels. In this cited work, it was
found that mural cell exposure to FGF-9 activated FGF receptor signalling, promoted cell
elongation, decreased apoptosis, increased the expression of PDGFR and Sonic
Hedgehog (SHH), and augmented the mural cell chemotactic response to PDGF-BB
(Figure 2-2) . Unlike FGF-2, FGF-9 was found not to stimulate angiogenesis in
subcutaneous implants, but instead it drives muscularization of angiogenic sprouts within
the implant and enhances the ability of the microvasculature to receive flow and resist
regression [99].
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Figure 2-2: FGF9-mediated microvessel maturation.
FGF9 stimulates mural cells to express Sonic Hedgehog, which signals the upregulation of
PDGFR- in an autocrine manner. PDGF-BB, the ligand of this receptor, which is
synthesized by the endothelial cell tubes, enhances the recruitment of FGF9-stimulated
mural cells. Hence, the FGF9-SHH-PDGFR axis mediates the migration of mural cells to
endothelial tubes resulting in microvessel maturation.

Figure 2-3 illustrates FGF-9−stabilization of nascent microvessels through mural cell
recruitment to ECs tubes. FGF-9 increases smooth muscle cell expression of the PDGF
receptor, through the SHH pathway, thereby enhancing the recruitment of smooth muscles
to nascent vessels. When FGF-9 was infused into ischemic mouse hind limb, the resulting
microvessels were found to be invested with more VSMCs than those generated in the
absence of FGF-9. In addition, FGF-9 injection had led to accelerated re-growth of muscle
mass, along with improved limb function, compared to control vehicle [83].
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Figure 2-3: FGF9−stabilization of nascent microvessels through mural cells
recruitment to endothelial cell tubes.
Used with permission from Macmillan Publishers Ltd: [Nat Biotechnol][83].

Angiogenic Growth Factors Delivery Technologies
The use of recombinant protein growth factors may be a preferred therapeutic strategy
compared with gene therapy [100]. Angiogenic growth factors have been delivered either
by bolus injection or infusion into systemic circulation or the tissues of interest. The short
half-life of these proteins results in low local availability that do not meet the spatial and
temporal design criteria [17, 101-103]. One approach to overcome such limitations is the
localized and sustained delivery of growth factors at the desired site from polymer-based
delivery systems.

2.9.1

Controlled Delivery of Angiogenic Factors from Polymer-based Systems

Biodegradable polymer vehicles incorporating growth factors can provide sustained
release into the site of interest yielding concentrations within the therapeutic range over a
period of days to months [17, 104]. Moreover, polymer properties can be readily tailored
to change the temporal and spatial release profiles, making polymer-based delivery systems
promising candidates for therapeutic angiogenesis [17, 105-107]. Polymers used in
controlled delivery of angiogenic factors include synthetic polymers such as poly(glycolic
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acid) (PGA), poly(lactic acid) (PLA), and their copolymer (PLGA) [104, 108, 109]. In
addition, natural polymers such as fibrin [110], collagen [111], alginate [112], chitosan
[113], gelatin [114], and other hydrogels [115] can be used in the fabrication of controlled
delivery systems. Delivery systems often comprise porous scaffolds, hydrogels or
microspheres according to the desired application [105, 116]. The fabrication method used
to produce the scaffold or vehicle can denature or inactivate the incorporated angiogenic
factors. Electrospinning together with gas-foaming techniques were reported to produce
vehicles that retain the bioactivity of incorporated and released growth factors [117-120].
Fibrin gel has been used as delivery system of growth factors such as nerve growth factor
[121], bFGF [122], VEGF [123], and transforming growth factor-beta [124]. Despite
positive results, the release kinetics from such fibrin delivery matrix remained uncontrolled
[3]. On the other hand, incorporation of thrombin and fibrinogen together with heparin in
fibrin gels demonstrated better control of the release rate of heparin-binding growth factors,
such as VEGF and FGF-2 [125], which can be explained by the fact that many angiogenic
growth factors are found associated with heparin in native ECM. Moreover, photoreactive
combinations of gelatin and heparin have also been employed to localize VEGF and FGF2 to polyurethane grafts [126]. Collagen and its derivative gelatin often have poor loading
capacity for growth factors. Heparin has been covalently attached to collagen to enhance
the capture of angiogenic growth factors in the matrix. The addition of glycosaminoglycans
alters the cross-linking density of the matrix and decreases the pore size limiting the burst
release of entrapped growth factors [3, 111]. Alginate microspheres can be employed for
sustained release of entrapped proteins. Protein loss during bead preparation has been a
major challenge for efficient drug delivery [3]. Microspheres of PLGA and poly(ethylene
glycol) have been formulated for controlled release of VEGF with subsequent evaluation
in vitro [104]. As with alginate microspheres, the exact processing parameters and
subsequent retention of bioactivity remains challenging. VEGF has also been delivered
from hydrocarbon stent coatings, which demonstrated increased EC growth [127].
Immobilization of growth factors has been adopted to induce specific and localized effect.
It can protect against cellular inactivation and digestion [128]. Immobilized bFGF onto
poly(ethylene glycol) diacrylate hydrogels has been reported to induce VSMC proliferation
and migration [129].
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2.9.2

Electrospun Fibers as Angiogenic Factor Delivery Vehicles

Electrospinnning is an established technique for scaffold fabrication that can prolong the
angiogenic factor release and overcome difficulties encountered with angiogenic factor
incorporation within conventional scaffolds, such as controlling the release profile and
retaining growth factor bioactivity. In the electrospinning process, a high voltage is applied
to the droplet of polymer solution to overcome the surface tension and enable the formation
of fibers with an average diameter ranging from the micrometer to the sub-micrometer
range. Desirable release profiles can be achieved by controlling the chemical nature of
polymers and bioactive molecules, size and morphology of fibers, porosity of fibrous
structure and their degradation rate, and initial drug-loading [130]. An appropriately
sustained growth factor release profile in combination with a nanofibrous scaffold could
positively influence stem cell behavior and fate [119]. Sahoo et al. [119] reported that
PLGA nanofibers incorporated with bFGF favored bone marrow stem cell attachment and
subsequent proliferation. In this case, cells cultured on coaxial electrospun fibrous
scaffolds demonstrated increased collagen production and upregulated gene expression of
specific ECM proteins, indicating fibroblastic differentiation. Casper et al. [131] used a
low molecular weight heparin (LMWH) grafted to poly (ethylene glycol) and electrospun
this conjugate within PLGA for bFGF delivery. Heparin retention within the graft structure
was increased as well as FGF retention with the conjugation versus LMWH alone. It has
been proposed that the resulting nanoscale features, that are achievable with
electrospinning, may be ideal for growth factor localization. Heparinized electrospun fibers
were reported to efficiently bind bFGF, sustaining its release and preserving its bioactivity
[120]. Chitosan/poly(vinyl alcohol) conjugated nerve growth factor scaffolds for potential
neural tissue engineering purposes were prepared using electrospinning and reported to
support cell attachment and proliferation [132]. Co-axial electrospun fibers offered both
topographical and biochemical cues for regenerative medicine applications. The plasma
factor VIII-releasing co-axial electrospun poly(urethane) fibers facilitated sustained
treatment of hemophilia via a non-viral tissue engineering approach [118]. Emulsion
electrospinning was adopted to embed bFGF into poly(ethylene glycol)-poly(DL-lactide)
ultrafine fibers with a core-sheath structure to promote the wound healing process [133].
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Moreover, bFGF was physically immobilized within gelatin electrospun scaffolds with
aligned or random fiber orientations. EC adhesion and orientation was found to be highly
dependent on scaffold fiber orientation and morphology, where the cells expressed
synthetic phenotype when seeded onto the aligned scaffolds, which is of a particular
importance in new blood vessel formation [134].
A family of biodegradable poly(ester amide)s (PEA)s was explored in our laboratory to
fabricate electrospun nanofibers [135, 136]. The rationale for exploring PEAs is that they
combine the favorable properties of both polyesters and polyamides – the tunability in the
degradation rate via the ester groups and mechanical strength via the hydrogen bonding of the
amide groups. The ester and amide linkages promote both hydrolytic and enzymatic
degradation, which should ensure a surface degradation mechanism [137], and this provides

better prediction and control over the release profile. In addition, PEAs with tailored
degradation rates can be synthesized with the careful selection of the monomers. Their

degradation by-products include amino acids, which are found physiologically, limiting
their potential systemic toxicity [138]. Unlike polyesters, PEA degradation results in less
acidic by-products, avoiding significant pH decrease in the tissues and thus decreased host
immune responses [139]. In this thesis, a PEA derived from the α-amino acid, Lphenylalanine, was utilized to fabricate dual-loaded electrospun fibers for therapeutic
angiogenesis application.

2.9.3

Spatio-temporal Controlled Delivery of Angiogenic Factors

Local concentration of angiogenic growth factors delivered by polymer-based delivery
systems can be tuned by modifying the physical or chemical properties of these systems.
The release of encapsulated growth factors is controlled by porosity, pore size, inter-pore
distance, the degree of cross-linking, and degradation rate of the delivery system [17]. Pore
size and porosity have also been found to affect host inflammation and angiogenesis [140].
Mooney and coworkers [141] reported that altering the composition of synthetic polymer
such as PLGA can control the degradation rate to produce differential VEGF release
profiles. Delivery systems can be designed to release angiogenic growth factors in
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response to specific signals from the cellular environment, including enzymes such as cell
secreted proteinases [142, 143] and mechanical stimulation [144]. Polymer-based systems
permitting sequential growth factors delivery; such as VEGF and PDGF-BB [95], VEGF
and Angiopoietin-1 [145], or FGF-2 and PDGF-BB [38], have been demonstrated to
promote mature and stable vessel formation more effectively than simultaneous delivery
of the growth factors.
Spatial gradients of growth factors in tissues of interest can be achieved by changing the
placement of polymer vehicles, immobilizing insoluble ligands to localize cells of interest,
or designing delivery systems to provide spatially distinct signals [17]. For example, a
porous bi-layered PLG scaffold system locally presenting VEGF alone in one spatial
region, and VEGF and PDGF-BB in an adjacent region was reported to produce spatially
different vessel morphologies [146]. Accordingly, presenting pro- and anti-angiogenic
factors at different sites in the polymer scaffold may produce diverse vascular structures
[17]. Coupling of cell adhesive ligands such as Arg-Gly-Asp (RGD) to the site of interest
can also be used to control the region of vessels formation [147], and the nano-scale
organization of RGD can affect EC adhesion and motility [148]. Novel 3D fabrication
techniques can offer more opportunities to control the geometry and design of polymerbased scaffolds [149], consequently making it possible to incorporate angiogenic growth
factor releasing vehicles into micro or nano-scale electromechanical devices to have more
accurate control over spatial and temporal presentation of these growth factors [150, 151].
Integrating therapeutic angiogenesis with nanomedicine strategies may also offer more
promising applications in regenerative medicine [152].

Safety of Angiogenic Growth Factor Delivery
Several safety concerns can arise from the delivery of angiogenic growth factors to induce
therapeutic angiogenesis for treatment of ischemic cardiovascular disease. These concerns
focus on the potential for pathological angiogenesis and the side effects of the delivered
factor [153]. Animal studies and early clinical trials suggested several typical side effects
associated with exposure to FGF-2 and VEGF. VEGF and FGF-2 are known to be
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associated with systemic hypotension that occurs in a dose-dependent fashion; in this
regard, the doses of FGF-2 leading to hypotension are substantially higher than for VEGF
[154, 155]. It can be attributed to the upregulation of nitric oxide synthase and increased
vessel wall permeability [156]. This has been shown in phase I trials at high doses or with
rapid infusion of the angiogenic factors. FGF-2 has also been associated with proliferative
membranous nephropathy leading to proteinuria in mice, but this has not been observed in
clinical studies [157]. It is probably related to FGF-2 deposition in the heparan sulphate
rich glomerular membrane [158]. For that reason, FGF-2 is not preferred to be used in
patients with decreased creatinine clearance. Also, the adverse effects of VEGF and FGF
include local oedema, anaemia, and thrombocytopenia [159, 160]. Growth factor gene
therapy is usually accompanied with concerns of inflammatory responses due to exposure
of patients to foreign genetic material and viral vectors [44, 46]. Over-expression of VEGF
in mice has been associated with the formation of angiomas and vascular tumors [161,
162]. The major concern is that the induction of angiogenesis may increase the risk of
cancer. This concern arises from the well documented role of angiogenesis in tumor growth
and metastasis [163]. To date, neither in vitro nor in vivo data exists to suggest that methods
of therapeutic angiogenesis increase the risk of neoplastic growth or metastases. Oncogenic
effects are not likely to occur with short-term dosing, appropriate patient selection, and
localized delivery [74, 164, 165].

Conclusions
Ischemic heart disease causes millions of deaths worldwide. Data in the literature suggest
that therapeutic angiogenesis may offer hope for ischemic heart disease patients who are
ineligible to standard revascularization techniques. Moreover, if this proves to be the case,
then expanded indications for therapeutic angiogenesis might then follow. Comprehensive
understanding of the basic biology of neovascularization in physiological and pathological
conditions will provide important information for the design of optimal delivery systems
in terms of growth factor concentration, spatial and temporal release profiles, and their
simultaneous or sequential presentation. Moreover, increased knowledge of the biological
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mechanisms that regulate blood vessels growth and maturation, which highlights the
complexity of molecular and cellular interactions taking place within the angiogenic
microenvironment, is essential for targeting both neovascular induction and maturation.
The combination of therapeutic angiogenesis with controlled delivery strategies could
provide a minimally invasive revascularisation strategy that may be a major advance in the
treatment of ischemic heart disease.
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Chapter 3
3

Controlled Delivery of Fibroblast Growth Factor-9 from

Biodegradable Poly(ester amide) Fibers for Building Functional
Neovasculature
Overview: This chapter discusses the fabrication and optimization of PEA electrospun
fibers and loading them with a model protein (BSA) and FGF9 using either blend or
emulsion electrospinning techniques and their characterization in terms of morphological
properties, in vitro release kinetics, bioactivity of the released growth factor, and cell
viability and metabolic activity.

Abstract
For building functional vasculature, controlled delivery of fibroblast growth factor-9
(FGF9) from electrospun protein-analog fibers is an appealing strategy to overcome
challenges associated with its short half-life. FGF9 sustained delivery could potentially
drive muscularization of angiogenic sprouts and help regenerate stable functional
neovasculature in ischemic vascular disease patients. Electrospinning parameters of FGF9loaded poly(ester amide) (PEA) fibers have been optimized, using blend and emulsion
electrospinning techniques. In vitro PEA matrix degradation, biocompatibility, FGF9
release kinetics, and bioactivity of the released FGF9 were evaluated. qPCR was employed
to evaluate platelet-derived growth factor receptor-β (PDGFRβ) gene expression in NIH3T3 fibroblasts, 10T1/2 cells, and human coronary artery smooth muscle cells cultured on
PEA fibers at different FGF9 concentrations. Loaded PEA fibers exhibited controlled
release of FGF9 over 28 days with limited burst effect while preserving FGF9 bioactivity.



A version of this chapter is published as a research article “Somiraa S. Said, J. Geoffrey Pickering and
Kibret Mequanint, Pharmaceutical Research (2014), 31(12); 3335-3347”. Adapted with permission from
Springer © 2014.
48

FGF9-loaded and unloaded electrospun fibers were found to support the proliferation of
fibroblasts for five days even in serum-depleted conditions. Cells cultured on FGF9supplemented PEA mats resulted in upregulation of PDGFRβ in concentration and cell
type-dependent manner. This study supports the premise of controlled delivery of FGF9
from PEA electrospun fibers for potential therapeutic angiogenesis applications.
Keywords: Electrospinning; Fibroblast growth factor-9; Poly(ester amide)s; Therapeutic
angiogenesis.

Introduction
Ischemic vascular diseases are characterized by inadequate delivery of blood and oxygen
to tissues; coronary artery disease affects the heart, cerebrovascular disease affects the
brain, and the peripheral arterial disease affects skeletal muscles and other internal organs
[1]. The principal pathological process causing ischemic diseases is atherosclerosis, which
is a progressive inflammatory condition that usually affects large arteries, in which the
accumulation of lipids, inflammatory cells, and fibrous material in the inner arterial wall
results in the occlusion of these arteries [2]. Some ischemic disease patients are ineligible
for standard revascularization techniques due to poor overall health status or underlying
comorbidities.

Furthermore,

a

significant

percentage

of

patients

undergoing

revascularization procedures do not meet the desired treatment outcome or experience
restenosis, resulting in a poor prognosis and diminished quality of life, necessitating novel
therapeutic alternatives for treatment of ischemic diseases [1].
Therapeutic angiogenesis, which includes the administration of growth factors for new and
stable blood vessel formation, is an appealing approach to simulate angiogenesis in order
to improve tissue perfusion and accelerate tissue regeneration in several pathological
conditions such as ischemic heart disease, critical limb ischemia, diabetic ulcers, and
delayed wound healing, leading to the functional recovery of ischemic tissues. However,
the short half-life of exogenously delivered growth factors results in their rapid clearance
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from the application site following their delivery in a soluble form as an injection or
infusion in the systemic circulation or tissue of interest [3]. One approach to overcome
such limitations is the controlled delivery of growth factors at the desired site from fibers
using either blend, coaxial or emulsion electrospinning techniques [4-7]. This can boost
the stability of the growth factors and enable the sustained release of angiogenic factors in
a biologically active form at the site of interest [8].
Fibroblast growth factor-9 (FGF9) or glial activating factor is one of the FGF superfamily
and relatively little is known regarding its physiological function [9]. It has higher
specificity to fibroblast growth factor receptor-2/-3 isoforms [9-11], and was shown to
demonstrate an elevated neointimal expression after arterial injury and contributes to
smooth muscle cell proliferation [10]. Recently, it has been reported that even though FGF9
did not itself stimulate angiogenesis, it was found to drive muscularization of angiogenic
sprouts and that its delivery imparts stability, longevity, and the ability to regulate blood
flow through vasoresponsiveness of the newly formed microvessels [12]. The FGF9induced layering of neovessels was suggested to be mediated by sonic hedgehog-PDGFRβdependent signaling and it enhanced the ability of the neovasculature to receive flow and
resist regression [12]. FGF9 delivery by means of an osmotic pump to ischemic hind limbs
promoted neovascular maturation and recovery of limb function [12]. Therefore, FGF9
delivery may be required in order to drive the angiogenesis process towards completion
since angiogenic growth factors by themselves cannot efficiently produce vasoreactive
neovessels [13]. Controlled-release biodegradable polymeric fibers can serve as a simple,
low-cost and efficient alternative for implantable mini-infusion pumps for the delivery of
FGF9, without the need of delivery system removal after consumption of the growth factor.
Poly(ester amide)s (PEAs), successfully synthesized in our laboratory, are protein-analog
polymers that were found to have the potential to promote vascular tissue regeneration
owing to their biomimetic properties and favorable degradation profiles [14], for which
bioactive molecules can be incorporated, potentially sustaining their release, enhancing
their efficacy, and accelerating favorable cell-material interactions. Degradation products
of PEAs derived from naturally occurring α-amino acids are nontoxic and can be well
metabolized by the body. Moreover, PEA degradation is accompanied by the release of
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less acidic by-products compared to polyesters, thus avoiding pH decrease in the vicinity
of the scaffold, usually resulting in inflammatory responses [15]. Nevertheless, surface
eroding PEA scaffolds exhibit linear drug release kinetics [16], which provides better
control of the drug release profile. Although electrospinning of a small number of PEAs
have been reported [17-19], these PEA fibers were either prepared from low-molecular
weight PEAs resulting in large diameter-fibers (from 0.64 to 3.5 µm) [17], or a polymer
blend was required for electrospinning, where polycaprolactone was added to L-alaninebased PEA as a viscosity modifier to facilitate electrospinning [18]. Moreover, in vitro
degradation studies of other alanine-based PEA electrospun fibers showed that they were
not practically degradable, where the weight loss was less than 6% after 305 days of
incubation in phosphate buffered saline at 37 °C [19].
In this study, amino acid-based biodegradable protein-analog electrospun PEA fibers have
been fabricated for controlled delivery of growth factors intended for therapeutic
angiogenesis applications. The goal here is to prepare FGF9-loaded protein-analog fibers
and characterize the fabricated fibers in terms of their morphological properties and in vitro
degradation. The in vitro release kinetics were also studied together with the bioactivity of
the released FGF9. The in vitro biocompatibility of the FGF9-loaded and unloaded
electrospun fibers was tested using NIH-3T3, 10T1/2, and human coronary artery smooth
muscle cells for potential therapeutic angiogenesis application

Materials and Methods
3.3.1

Materials

L-Phenylalanine, p-toluenesulfonic acid monohydrate, sebacoyl chloride, 1,4-butanediol
and sodium carbonate (Alfa Aesar, Ward Hill, MA). Solvents, such as toluene, ethyl
acetate, dimethyl sulfoxide (DMSO), chloroform (CHCl3) and glass distilled
dichloromethane (Caledon Laboratories, Georgetown, ON) were used without further
purification. Bovine serum albumin was purchased from Sigma-Aldrich (Milwaukee, WI)
and BCA protein assay kit from Thermo Scientific Pierce Inc. (IL, USA). Recombinant
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human fibroblast growth factor-9 (FGF9) and human FGF9 DuoSet ELISA kit were
purchased from Cedarlane (Burlington, ON).

3.3.2

Synthesis of Poly(ester amide) by Interfacial Polymerization

The poly(ester amide) was prepared as previously reported [14]. In the first step, di-ptoluenesulfonic acid salt monomer was prepared by acid-catalysed condensation. A
suspension of L-phenylalanine (60.5 mM, 2.2 equivalents), p-toluenesulfonic acid
monohydrate (66 mM, 2.4 equivalent), and 1,4-butanediol (27.5 mM, 1 equivalent) in
toluene (100 mL) was heated to 140 ºC with stirring in a flask equipped with a Dean-Stark
trap. The solution was heated at reflux for 48 h, and then the solvent was removed under
vacuum. The resulting material was filtered and washed with toluene. The monomer was
purified by dissolving in boiling deionized water (300 mL) followed by hot filtration, and
the solution was left to recrystallize overnight at 4 ºC. The purification step was repeated;
afterwards, the monomer crystals were filtered and dried under vacuum.
In the second step, sebacoyl chloride (5 mM, 1 equivalent) was dissolved in glass distilled
anhydrous dichloromethane (15 mL) and the solution was added drop-wise to an aqueous
solution (15 mL) containing di-p-toluenesulfonic acid salt monomer (5.0 mM, 1
equivalent) and sodium carbonate (10 mM, 2 equivalents), and allowed to react for 12 h.
Upon completion of the reaction, the solution was rotovapped. The polymer was then
washed with deionized water prior to purification via Soxhlet extraction with ethyl acetate
for 48 h followed by drying under vacuum.

3.3.3

Fabrication of PEA Electrospun Fibers

The electrospinning setup was equipped with a High Voltage DC Power Supply (ES30P,
Gamma high voltage, USA), a glass syringe (Becton, Dickinson and Co., 0.5 cc, NJ, USA)
with a blunt-tip stainless steel needle (conducting spinneret) controlled by a syringe pump
(KD101, KD scientific, USA), and a static collector covered with aluminum foil. The
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process parameters including spinneret diameter (18 - 22 G) and applied voltage (15 - 20
kV), and the formulation parameters including polymer concentration (5.5 - 7 %w/w) and
solvent composition (Chloroform-to-dimethyl sulfoxide ratio) were optimized, in order to
obtain bead-free fibers with uniform fiber diameter distribution.

3.3.4

Characterization of PEA Electrospun Fibers

Morphological analysis of the PEA fibers was performed using scanning electron
microscopy (S-3400N SEM, Hitachi, Japan). Electrospun fibrous mat samples were
sputter-coated with gold/palladium (K550X sputter coater, Emitech Ltd., UK) and scanned
at a working distance of 10 mm and a constant accelerating voltage of 20 kV. Three SE
micrographs of the electrospun mats were analysed using computerised ImageJ software
(NIH, Bethesda, MD, USA) to quantitatively determine mean fiber diameter from ten
random measurements for each image. For transmission electron microscopy (Phillips
CM10 TEM), the fibers were electrospun directly on the TEM grids for 30 sec, and the
samples were examined at 80 kV.

3.3.5

In vitro Degradation Study

Samples of the fibrous mats (1 × 1 cm2) were placed in a screw-capped glass vials filled
with 10 mL of phosphate buffered saline (PBS 50 mM, pH 7.4) and removed at predetermined time-points, rinsed with deionized water and vacuum dried for 48 h at room
temperature for further analyses. Samples at the different degradation time-points were
analysed morphologically using SEM. The weight loss was determined by the following
equation: Mass loss =[

(𝑀𝑖−𝑀𝑡)
𝑀𝑖

] × 100%, where, Mi is the initial dry weight of the fibrous

mat at time 0 and Mt is the dry weight of the sample at the specific degradation time (after
drying under vacuum). The molecular weights of the PEA fibers before and after
degradation were determined using a Waters system gel permeation chromatography
(GPC) equipped with two PLgel 5µm (300 × 1.5 mm) columns at 85 °C and connected to
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a PLgel guard column (Waters Ltd, Mississauga, ON). The eluent used was N,Ndimethylformamide (DMF) with 10 mM lithium bromide and 1% (v/v) triethylamine, and
samples were injected (100 μL) at a flow rate of 1 mL/min and calibrated against
polystyrene standards. Additional degradation studies were carried out in conditioned
smooth muscle cell growth medium (CSmGM); human coronary artery smooth muscle
cells (HCASMCs) were cultured in SmGM for 48 h, then the media was collected and used.
Samples of 1 × 1 cm2 fibrous mats were immersed in 1 mL of the degradation medium at
37 ºC, and the media were refreshed every week. Samples at different degradation timepoints were removed, rinsed with deionized water, vacuum dried at room temperature and
analyzed morphologically using SEM. To rule out the effect of the incubation temperature,
dried PEA fiber mats were kept in a vial at 37 oC as a control.

3.3.6

Loading PEA Fibers with Model Protein and Fibroblast Growth Factor-9

Bovine serum albumin (BSA) was incorporated into the PEA fibers using blend or
emulsification electrospinning [5, 6]. The electrospinning parameters were adopted from
the previously conducted studies for unloaded fibers. Briefly, the PEA was dissolved in
chloroform and dimethyl sulfoxide (DMSO) at a ratio of (9:1). The polymer solution (0.5
ml) was electrospun using a high voltage DC power supply set to 20 kV and a syringe with
a blunt-tip stainless steel spinneret (22 gauge) kept at 8 cm from the grounded collector.
The flow rate was kept at 0.1 mL/h using a syringe pump. In case of the blend
electrospinning, BSA was dispersed in DMSO (1 µg/µL) and 100 µL were added to the
polymer solution. While, for the emulsion electrospinning, 10 µL of stock BSA solution in
PBS (10 µg/µL) were dropped and ultrasonicated in the polymer solution for 30 min in an
ice bath. The same protocol was adopted for FGF9 loading, except for the lower initial
loading (3 µg FGF9/ 0.5 mL polymer solution).
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3.3.7

Determination of Percentage Entrapment Efficiency

Four milligrams of loaded PEA fibers were dissolved in 0.5 mL of chloroform and the
tube was vortexed to dissolve the polymer. Afterwards, 2.5 mL of PBS (pH 7.4) were added
to extract the protein, and the system was centrifuged at 2000 rpm for 5 min to separate the
organic and aqueous phases. The aqueous phase was collected for BSA or FGF9
quantification using BCA protein assay kit (Thermo Scientific Pierce Inc., IL, USA) and
ELISA assay kit (R&D systems, Inc., MN, USA), respectively. Three independent
experiments on different PEA-loaded fiber batches each conducted in triplicate (n=9) were
used to determine the percentage entrapment efficiency (% E.E.).

3.3.8

In vitro Release Study of BSA and FGF9-loaded PEA Electrospun Fibers

Samples of 1 × 1 cm2 fibrous mats were placed in a 24-well plate, and incubated with 1 ml
of phosphate-buffered saline (PBS 50 mM, pH 7.4) under continuous agitation (100
strokes/min), in a thermostatically controlled micro-plate shaker (VWR, USA) at 37°C. At
pre-determined time intervals, the supernatant was collected and replenished with an equal
volume of fresh buffer. The supernatants were immediately frozen at − 80°C until further
measurements. The amount of BSA released was quantified by micro BCA protein assay
kit (Thermo Scientific Pierce Inc., IL, USA), while the amount of FGF9 released was
quantified by ELISA assay kit (R&D systems, Inc., MN, USA). The absorbance was
measured using a micro-plate reader (UVM 340, Montreal Biotech Inc., Canada) and the
unknown concentration was determined from a pre-constructed calibration curve and the
% E.E. data.

3.3.9

Bioactivity Assay of the Released Growth Factor

Bioactivity of the released growth factor from the electrospun scaffolds was assayed by in
vitro evaluation of (NIH-3T3 cell line) mouse embryonic fibroblast metabolic activity.
NIH-3T3 cells were seeded in 96-well plates at a density of approximately 3000 cells/well
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with 100 µL/well of advanced DMEM (GIBCO®, Invitrogen, Burlington, ON, Canada)
containing 5% FBS, 1% antibiotics and 2 mM L-glutamine, in addition to 100 µL of the
released FGF9 in PBS. After an incubation time of 48 h, cell metabolic activity was
determined by MTT assay following the manufacturer’s protocol (Vybrant®, Invitrogen,
Burlington, ON, Canada). As a positive control, soluble FGF9 was added to the NIH-3T3
cells in amounts equivalent to those released from the FGF9-loaded scaffolds. The amount
of added growth factor was calculated from the in vitro release data, combining release
time points into: early-released FGF9 (from Day 1 to Day 14) and late-released FGF9 (from
Day 15 to Day 28) for both blend and emulsion electrospinning techniques. Cells cultured
without FGF9 served as a negative control.

3.3.10

Cell Viability and Confocal Microscopy

Cell viability and metabolic activity on 2D PEA films (20 µL of 1% w/v PEA in DMF
solvent casted), unloaded and FGF9-loaded 3D PEA electrospun scaffolds were quantified
by MTT colorimetric assay. Circular patches (4 mm in diameter) of electrospun mats on
aluminium foil were punched and affixed to a 96-well cell culture plate (BD Falcon™,
Franklin Lakes, NJ) using silicone grease, sterilized by immersion in 70% ethanol (200
µL) for 30 min, and allowed to dry for one hour under germicidal UV light, before
conditioning overnight in Hank’s balanced salt solution (HBSS, 200 µL; Invitrogen
Canada, Burlington, ON). NIH-3T3 cells were seeded onto samples at an initial cell density
of approximately 3000 cells/well and cultured for five days in advanced DMEM containing
5% FBS or serum-depleted conditions, and maintained in a humidified incubator at 37 °C
and 5% CO2. At pre-determined time points, the medium was refreshed (100 µL), followed
by the addition of 10 µL of 12 mM MTT solution to each well to make the final
concentration 1.10 mM and then incubated at 37°C for 4h. Yellow MTT salts are reduced
to water-insoluble purple formazan by metabolically active cells. Afterwards, 100 µL 10%
(w/v) SDS/HCl was added to solubilize the formazan, and further incubated at 37 °C for
18 h. Finally, the colored product was transferred to 96-well plate and the absorbance was
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recorded at 570 nm by a micro-plate reader. Controls of TCPS were included in the
experiments.
For confocal microscopy, NIH-3T3 fibroblasts, 10T1/2 cells, and HCASMCs were seeded,
in 24-well plate at an initial cell density of approximately 2000 cells/cm2, on control glass
coverslips, PEA films, FGF9-loaded PEA fibers, and PEA fibers with exogenous soluble
FGF9, for three days. Cells were washed with pre-warmed PBS immediately prior to fixing
at ambient temperature for 15 min in 4% formaldehyde solution (1 mL; EMD Chemicals)
in divalent cation-free PBS. Following three washes in PBS, HCASMCs were
permeabilized with 0.1% Triton X-100 (0.5 mL; VWR International, Mississauga, ON) in
PBS for 5 min and again washed three times with PBS. The cells were incubated with 1%
BSA in PBS (0.5 mL; Sigma-Aldrich, Oakville, ON) for 30 min at ambient temperature
prior to their incubation with AlexaTM Fluor 568-conjugated phalloidin (1:50 dilution;
Invitrogen Canada, Burlington, ON) in the dark for 1 hour at ambient temperature followed
by another three washes with PBS. The cells were then counterstained with 4′-6-diamidino2-phenylindole dyhydrochloride (DAPI, 300 nM in PBS, 0.5 mL; Invitrogen Canada,
Burlington, ON) for 5 min to label the nuclei and again washed three times with PBS. No.1
coverslips were mounted on microscope slides with Trevigen® Fluorescence Mounting
Medium (Trevigen INC., Gaithersburg, MD). Samples were analyzed with a Zeiss LSM 5
Duo confocal microscope with nine laser lines and appropriate filters (Carl Zeiss, Toronto,
ON, Canada).

3.3.11

RNA Isolation and Quantitative Real-time PCR Analysis

Real-time Polymerase Chain Reaction (qPCR) combined with reserve transcription was
used to quantify messenger RNA (mRNA) expression of PDGFR-β in NIH-3T3 cells
grown on control (TCPS), PEA fibers, FGF9-loaded PEA fibers, and PEA fibers with
exogenous soluble FGF9, at a density of 2.5 × 105 cells/sample, for 24 h. Moreover, q-PCR
was employed to study the effect of FGF9 concentration gradient on PDGFR-β gene
expression in different cells (NIH-3T3, 10T1/2, and HCASMCs) grown on control (TCPS)
and PEA fibers with exogenous soluble FGF9 of different concentrations (0, 8, 25, and 50
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ng/mL). Total RNA from the cells was extracted using Trizol® reagent (Invitrogen,
Burlington, Canada) following the manufacturer’s protocol. Complementary DNA
(cDNA) was synthesized using 1µg of total RNA primed with oligo12-18 as described in
SuperScriptTM (Invitrogen, Canada). Quantitative real-time PCR was conducted in 10 µl
reaction volumes, using a CFX-96 Touch™ Real-time system C1000 Thermal Cycler (BioRad, Mississauga, Canada) and gene expression of mouse and human PDGFR-β were then
determined with iQTM SYBR® Green Supermix (Bio-Rad) according to the recommended
protocol

of

the

manufacturer.

5′- GGAGATTCGCAGGAGGTCAC-3′,

reverse

5′- ATAGCGTGGCTTCTTCTGCC-3′,

GAPDH

5′- GTGGTCTCCTCTGACTTCAACA-3′,
5′- TTGCTGTAGCCAAATTCGTTGT-3′.

forward

PDGFR-β

primer:
forward

reverse
Amplification

primer:

entailed

primer:
primer:

40

cycles

of:

denaturation 95°C (15 s), annealing 55°C (60 s), and extension 72°C (30 s). The relative
mRNA expression in the cells was normalized to the housekeeping gene glyceraldehyde3-phosphate dehydrogenase (GAPDH) with at least three repeats per experimental group
and expressed as a relative ratio using the CFX ManagerTM 3.0 analysis software (Bio-Rad,
Mississauga, Canada).

3.3.12

Statistical Analysis

Data is presented as mean ± SEM for experiments conducted in triplicate. Statistical
analysis was conducted with t-test or one-way ANOVA followed by Tukey’s multiple
comparison test using GraphPad Prism 4 software (GraphPad Software, Inc., CA, USA).
Probability values less than 0.05 were considered statistically significant.
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Results and Discussion
3.4.1

Synthesis of PEA by Interfacial Polymerization

In this study, the PEA was synthesized by interfacial polymerization as previously reported
and the results were consistent with previous data [14]. The synthesized PEA, whose
chemical structure is shown in Figure 3-1 was designated as “8-Phe-4”, whereby the 8
stands for the number of methylene groups contributed by the sebacic acid (diacid), the
Phe is designated for L-phenylalanine (amino acid) and the 4 represents the number of
methylene groups in the butanediol moiety (diol). The structure of 8-Phe-4 was confirmed
through 1H NMR. Interfacial polymerization is an irreversible condensation reaction
occurring at the interface between two immiscible liquids; one of them is usually a water
phase containing the di-functional monomer and inorganic base to activate the diol and
neutralize the by-product acid, the other phase is an organic solvent containing the diacid
chloride. Interfacial polymerization is preferred because it is rapid, less affected by
impurities, and produces PEAs of higher molecular weights than solution
polycondensation reactions [20].

Figure 3-1: Chemical structure and corresponding H1-NMR of 8-Phe-4.
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3.4.2

Fabrication and Optimization of PEA Electrospun Fibers

PEA fibers were prepared using a solution electrospinning technique. The goal was to
develop bead-free fibers from high molecular weight-PEA and optimize the
electrospinning parameters to obtain fibers of average fiber diameter between 100 - 500
nm, in order to mimic the extracellular matrix fiber diameter. It is clear from the
electrospinning processes literature that the structure and morphology of the produced
fibers are determined by a synergistic effect of formulation and process parameters.
Formulation parameters including the effect of polymer concentration and solvent
composition on fiber morphology were studied. Increasing the polymer concentration in
100% chloroform (CHCl3) from 5.5 to7% w/w, electrospun at 8 cm/20 kV, 22 G, and 0.1
mL/h flow rate resulted in increasing the average fiber diameter from 445 to 655 nm as
illustrated in Figure 3-2 (A-C). This also led to decreased bead formation, where they
transformed from spherical-shaped beads to spindle-like beads to defect-free fibers. This
is consistent with previous data reporting that increasing the polymer solution viscosity by
increasing its polymer concentration yielded uniform fibers with fewer beads and junctions
[21]. However, at polymer concentration of 7% w/w, the polymer solution was too viscous,
and chloroform evaporated too fast (B.P. = 61°C), which resulted in drying out of the
polymer at the needle tip. This phenomenon was previously reported for concentrated
solutions (and therefore too viscous) [22], which in this study interrupted the
electrospinning process several times, demanding for an alternative solvent system.

Regarding the effect of solvent composition and conductivity on the fiber morphology, the
use of a binary solvent system of chloroform and dimethylsulfoxide, CHCl3/DMSO (9:1),
instead of 100% CHCl3 resulted in eliminating the beads as illustrated in Figure 3-2 (D-F).
This can be attributed to the high dielectric constant of DMSO (ε = 46.6) contributing to
the increased conductivity of the polymer solution. It has been shown that increasing the
polymer solution conductivity can be used to produce more uniform fibers with fewer
beads, and solvents that had sufficiently high values of dielectric constant were found to
be used successfully in electrospinning [21, 23]. Further increase in the DMSO
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concentration resulted in fiber fusion, due to residual DMSO that could not evaporate (B.P.
= 189 °C) from the polymer solution before the fibers hit the grounded collector.

Figure 3-2: Optimization of formulation electrospinning parameters.
Effect of polymer concentration on fiber morphology and fiber diameter, 8-Phe-4 in CHCl3
(A) 5.5% w/w, (B) 6% w/w, and (C) 7% w/w. Effect of solvent composition on fiber
morphology and diameter, 6% w/w 8-Phe-4 in CHCl3/DMSO ratio of (D) (10:0), (E) (9:1),
and (F) (8:2), electrospun at 8cm/20kV, 22 G, and 0.1 mL/h flow rate.

Processing parameters such as the applied voltage and spinneret diameter were also
studied. Figure 3-3 (A-C) illustrates the effect of the applied voltage on fiber morphology
and diameter. In the case of single solvent system of CHCl3, reducing the applied voltage
from 20 to 15 kV resulted in decreased fiber diameter from 380 to 255 nm; however, it did
not affect the fiber morphology. It has been shown that increased voltages produces jets
with larger diameters and ultimately leads to the formation of several jets and the presence
of beads in many polymeric systems [21]. In regards to the effect of spinneret diameter,
6% w/w PEA in CHCl3/DMSO (9:1) was electrospun at 20 kV, 8cm, and 0.1 mL/h flow
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rate with increasing needle gauge from 18 to 22 gauge, which corresponds to decreasing
the spinneret diameter. This resulted in a reduction in the mean fiber diameter from 345 to
250 nm Figure 3-3 (D-F) and more uniform fiber diameter distribution as shown in Figure
3-3 (G-I). Based on the optimization of PEA electrospun fibers data, the elelectrospinning
parameters were fixed at 6% w/w PEA in CHCl3/DMSO (9:1), electrospun at 20 kV, 8cm,
22 guage needle, and 0.1 mL/h flow rate in all subsequent experiments.

Figure 3-3: Optimization of process electrospinning parameters.
Effect of applied voltage on fiber morphology and diameter, electrospun fibers of 6% w/w
8-Phe-4 in CHCl3 at (A) 20 kV, (B) 17 kV, and (C) 15 kV. Effect of spinneret diameter on
fiber morphology and diameter, 6% w/w 8-Phe-4 in CHCl3/DMSO (9:1) was electrospun
from (D) 18 gauge, (E) 20 gauge, and (F) 22 gauge needle. Histograms of fiber diameter
distribution for 8-Phe-4 fibers electrospun from (G) 18 gauge, (H) 20 gauge, and (I) 22
gauge spinneret.
62

3.4.3

In vitro Degradation Study

Scaffold degradation in phosphate buffered saline (pH 7.4) at 37 ºC for a period up to four
weeks was examined qualitatively using scanning electron microscopy and quantitatively
by mass loss determination and molecular weight analysis using GPC. The effect of
temperature alone during the degradation of the fibers was excluded by incubating control
dry fiber mats at 37 ºC inside a glass vial. Since the glass transition temperature of 8-Phe4 is 41 ºC, no observable changes on the fiber morphology such as fiber flattening and
subsequent fusion over the 28 days was anticipated (top panel in Figure 3-4 A).

Figure 3-4: In vitro degradation of PEA electrospun fibers at 37 ºC for 28 days.
(A) SE micrographs for fibers in PBS (pH = 7.4) and conditioned human smooth muscle
cell growth medium, the control is dry PEA fibers kept at 37 ºC. (B) Percentage mass loss
of PEA fibers in PBS (pH = 7.4) at 37 ºC at different time points (n=3) and (C) molecular
weight analysis using gel permeation chromatography.
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Scanning electron (SE) micrographs showed that scaffolds incubated in PBS preserved
their fibrous structure over the four-week study period, with negligible morphological
changes when compared to the control at 37 ºC (middle panel in Figure 3-4 A). Moreover,
quantitative analysis showed 21% mass loss over the 28-day study period together with
insignificant change in average number molecular weight (Mn) over the four weeks (Figure
3-4 B and C). When these samples were incubated in PBS for 84 days (12 weeks), the
fibers lost 48% of their mass while the molecular weight remained nearly constant. The
linear decrease in mass (r2 = 0.99), coupled with constant molecular weight indicate that
the PEA scaffold degradation is dominated by surface erosion [18, 24]. The polydispersity
indices of the samples during the incubation time in PBS for 12 weeks were 2.88 ± 0.15,
further supporting the absence of bulk degradation. Additionally, the effect of bio-relevant
media on the degradation of the PEA fibers was studied, so additional degradation studies
were carried out in a conditioned smooth muscle cell growth medium (CSmGM); human
coronary artery smooth muscle cells (HCASMCs) were cultured in SmGM for 48 h, in
which the HCASMCs would have consumed the nutrients necessary for their growth and
secreted their metabolites and other products relevant to growth in culture, then the media
was collected and used for the degradation study. The SE micrographs showed that the
fibers did withstand this bio-relevant medium with some fiber swelling and fusion starting
from Week 3 (bottom panel in Figure 3-4 A). The in vitro degradation data suggests that
surface eroding PEA electrospun fibers can be employed for controlled delivery of
bioactive molecules in biorelevant conditions.

3.4.4

In vitro Release Study of Loaded PEA Electrospun Fibers

The model protein, bovine serum albumin (100 µg BSA/cm2), was successfully loaded into
the PEA fibers using blend or emulsification electrospinning [5, 6]. The percentage
entrapment efficiency (% E.E.) for blend and emulsion electrospun BSA-loaded fibers was
93% ± 3 and 73% ± 4, respectively. The lower entrapment efficiency for the emulsion
electrospun fibers is related to the relatively higher viscosity of the emulsified
protein/polymer mixture compared to the blend where the protein was dissolved.
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Transferring a more viscous emulsion from an emulsification vial to an electrospinning
syringe causes some material loss. The residual protein/polymer solution left on the inner
wall of the syringe after electrospinning also accounts for some material loss.
Samples of 1 × 1 cm2 fibrous mats were placed in a 24-well plate, and incubated with 1
ml of phosphate-buffered saline (PBS 50 mM, pH 7.4) under continuous agitation (100
rpm/min) at 37 °C. At predetermined time intervals, the amount of BSA released was
quantified by BCA protein assay kit. BSA release was sustained over the 28-day study with
a limited burst effect and 80% BSA liberation from the blend electrospun BSA-loaded PEA
fibers (Figure 3-5 A). Given that the mass loss during the 28 days is 21%, the higher BSA
release is related to its higher initial protein loading. Incorporation of higher amounts of a
protein into the fibers is believed to be a driving force for protein molecules to migrate
toward the surface of the fiber during electrospinning [25]. The absence of burst release
highlighted BSA uniform entrapment with the polymer solution [26], resulting in perfect
inclusion within the fibers [27], while the sustained release pattern confirmed the adequate
structural integrity of the fibers throughout the study. For emulsion electrospun fibers, the
release profile showed a decreased BSA release rate in comparison with blend electrospun
fibers, reaching 37% at Day 28. This is predictable based on the notion that BSA is
encapsulated in the aqueous vesicles (as demonstrated in Figure 3-5 C), which can be
referred to as a “diffusion-across-a-barrier type release system” [16]; this requires the
degradation of the polymeric matrix, then subsequent diffusion of BSA from the vesicles
across the outer barrier layer. During an emulsion electrospinning process, the emulsion
droplets move from the surface to the center to achieve their highest accumulation along
the axial region [6, 28]. This inward migration of emulsion droplets is caused by rapid
evaporation of the solvents during electrospinning. As the organic solvent evaporates faster
than water, the viscosity of the outer layer of a fiber increases more rapidly than that of its
inner layer resulting in a viscosity gradient between the aqueous droplets and the polymer
matrix, which directs the emulsion droplets to settle into the fiber core rather than on the
surface [16, 29].
BSA-loaded PEA fibers prepared by both electrospinning techniques followed a timedependent power law function:

𝐌𝐭
𝐌∞

= 𝐤 𝐭 𝐧 , where,
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𝐌𝐭
𝐌∞

is the fractional release, k is a

structural/geometric constant, t is the time and n is the release exponent representing the
release mechanism. The n values of blend and emulsion electrospun BSA-loaded fibers
were 0.62 and 0.58, respectively. For cylindrical constructs (for which the individual fiber
can be modelled), an n value between 0.45 and 0.89 indicates a coupled matrix degradation
and biomolecule diffusion release mechanism [30].

Figure 3-5: In vitro release study of (A) BSA-loaded PEA fibers and (B) FGF9-loaded
PEA fibers, using blend and emulsion electrospinning techniques, in PBS (pH=7.4) at
37 ºC (n=3).
(C) TEM of BSA-loaded PEA fibers and (D) TEM of FGF9-loaded PEA fibers, using the
emulsion electrospinning technique (arrows are pointing to the aqueous vesicles). (E)
Bioactivity study of FGF9 released from FGF9-loaded PEA fibers using MTT assay. Tworelease time points were tested; early-released FGF9 (from Day 1 to Day 14) and latereleased FGF9 (from Day 15 to Day 28) for blend and emulsion techniques. Positive
controls of soluble FGF9 were included in the experiment. Data represents mean ± SEM
from three independent experiments (* p < 0.05).
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Following the proof-of-concept of incorporating a model protein into PEA electrospun
fibers, FGF9 was loaded into the PEA fibers adopting both electrospinning techniques. The
% E.E. of FGF9 was 86% ± 3 and 80% ±3 for blend and emulsion electrospun FGF9loaded fibers, respectively, using ELISA kit. FGF9-loaded fibers showed a similar release
profile (Figure 3-5 B) with a significant decrease in the overall release rate, due to the lower
initial protein loading (~120 ng/cm2). Similarly, the release exponent for blend and
emulsion electrospun FGF9-loaded fibers was 0.67 and 0.59, respectively, indicating also
a non-Fickian diffusion mechanism. Although the ultimate goal is to deliver FGF9 in vivo,
BSA release studies were also conducted in this work. The rationale for using BSA was
two-fold: i) it is a widely studied model protein in controlled-release studies and, ii) it is a
large protein (66.5 kDa) compared with FGF-9 (23 kDa) allowing us to study the capability
of PEA fibers to release proteins of different sizes in a similar mechanism. The data (Figure
3-5 A and B) showed the release mechanism for both proteins was the same suggesting
that PEA electrospun fibers had shown versatility for loading different bioactive molecules
(BSA and FGF9). The ability to introduce bioactive molecules into these fibrous
electrospun meshes, through these aqueous pouches opens a new path to therapeutic agent
delivery.

3.4.5

Bioactivity Assay of the Released Growth Factor

A metabolic activity-based assay was used to assess the bioactivity of FGF9 released at
early (Day 1 - Day 14) and late (Day 15 - Day 28) collective time points from the PEA
electrospun fibers using blend and emulsion techniques. The proliferating cell number was
determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay on NIH-3T3 fibroblasts incubated for 48 h with media containing released FGF9 or
equivalent amounts of soluble FGF9 calculated from the in vitro release data (positive
control). There was no significant difference (p < 0.05) in metabolic activity between the
released and control FGF9 (Figure 3-5 E). These results indicate that FGF9 released from
the fibers, prepared either by blend or emulsion techniques, was bioactive up to 28 days.
It is worth noting that the emulsion late-released (ELR) time point did not show a
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significant difference from the untreated control (no FGF9 added), which can be attributed
to the lower released amount of FGF9 in case of ELR in comparison with the other three
tested conditions.

3.4.6

Cell Viability and Confocal Microscopy

For evaluation of the PEA electrospun fibers in vitro biocompatibility as potential drug
delivery vehicle for bioactive molecules, cell viability on FGF9-loaded 3D fibers was
assessed using the MTT assay and compared to 2D PEA films and unloaded 3D fibers. For
this section and the following one, FGF9-loaded PEA fibers prepared by emulsion
electrospinning instead of blend electrospinning were used for two reasons: (i) to provide
a maximum protection for FGF9 from the organic solvent (i.e. chloroform) during
electrospinning, (ii) the long-term goal is to use the fibers as a dual growth factor delivery
system (the first one for inducing angiogenic sprout formation and the second one to recruit
mural cells for neovessel maturation and functionality after the formation of the endothelial
tubes). Since FGF9 release is needed for neovessel maturation, its delayed release is
beneficial.
As shown in Figure 3-6, 2D PEA films, and both FGF9-loaded and unloaded fibers
supported fibroblast viability for up to five days, in the case of 5% FBS (Serum+)
conditions. In the case of serum-depleted (Serum−) conditions, the unloaded and FGF9loaded 3D PEA fibers maintained cell viability and metabolic activity through the five-day
study, whereas 2D PEA films supported only the survival of cells. Baker and Southgate
[31] attempted to culture stromal cells on 3D polystyrene fibers in serum-depleted
conditions, but stromal cells failed to adhere to the polystyrene fibrous scaffold in the
absence of serum; in contrary to this, PEA electrospun fibers were able to support
metabolically active fibroblasts in serum-depleted conditions, which could be attributed to
potential peptide linkages imparted by the amino acid-based PEA fibers.
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Figure 3-6: NIH-3T3 cell viability study on 2D PEA films (1% w/v), unloaded and
FGF9-loaded 3D PEA emulsion electrospun fibers for 5 days, in Serum+ (5% FBS)
and Serum- (serum depleted; 0.05% FBS) conditions, using MTT assay.
Data represents mean ± SEM from three independent experiments. Student t-test was
conducted between PEA fibers group and FGF9-loaded PEA fibers group at the same
conditions and the same time point (* p < 0.05).

To further assess the PEA electrospun fibers as a potential sustained-delivery vehicle for
FGF9, the interactions with different cell types (NIH-3T3, 10T1/2, and HCASMCs) were
examined using confocal microscopy. FGF9 has reported proliferative effect on 3T3 [32,
33] and smooth muscle cells [10, 12]. As for 10T1/2 cell line, it is a smooth muscle
precursor cell type that is commonly used for in vitro SMC phenotype studies because of
its ability to maintain a stable phenotype in culture and even can be pushed toward an SMC
state [34]. The cells showed good attachment and spreading on glass control and 2D PEA
surfaces, and displayed interaction and infiltration in case of the 3D PEA electrospun fibers
either FGF9-loaded or with exogenous supplementation of FGF9 as shown in Figure 3-7.
The PEA fibers had inherent autofluorescence in the green channel, which was obscured
in case of HCASMCs (Figure 3-7 K&L) due to the use of different culture medium
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(Medium 231 supplemented with SMGS, GIBCO®, Invitrogen, Burlington, ON, Canada).
Biodegradable PEAs have been previously reported to support attachment, spreading, and
proliferation of human coronary artery smooth muscle cells, bovine aortic endothelial cells,
and fibroblasts [14, 18, 35, 36]. Together with the fact that 3D scaffolds play an important
role in guiding cells to produce their own extracellular matrix and control phenotype
differentiation [37, 38], by providing both mechanical and biological cues, PEA
electrospun fibers were found to support cell growth even in serum-depleted conditions.
This data highlights the potential expanding applications of PEA fibers in drug delivery
and tissue engineering.

Figure 3-7: Confocal microscopy images of NIH-3T3, 10T1/2, and HCASMCs.
Cells seeded at 2000 cells/cm2 for 3 days on glass coverslips (control), PEA films, PEA
fibers with exogenous FGF9, and FGF9-loaded PEA fibers cultured in Serum+ media,
showing F-actin (red), nuclei (blue), and PEA fibers (green). Scale bar = 40 μm.
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3.4.7

RNA Isolation and Quantitative Real-time PCR Analysis

To understand the signaling pathways underlying the reported FGF9-induced investment
of neovessels by SMCs, the expression of platelet-derived growth factor receptor-β
(PDGFRβ), which is one of the downstream signaling molecules in FGF9-stimulated
SMCs was studied. PDGFRβ is a well-documented regulator of SMC migration [39] and
therefore a potential mediator of FGF9-induced vessel maturation. Real-time Polymerase
Chain Reaction (qPCR) preceded with reserve transcription was used to quantify
messenger RNA (mRNA) expression of PDGFRβ in NIH-3T3 cells grown on control
(TCPS), PEA fibers, FGF9-loaded PEA fibers, and PEA fibers with exogenous soluble
FGF9, at a density of 2.5 × 105 cells/sample, for 24 h. q-PCR analysis of PDGFRβ
expression showed insignificant difference between NIH-3T3 cells seeded on PEA fibers,
FGF9-loaded fibers, or PEA fibers with exogenous FGF9 (~2.5 ng/mL, equivalent to the
amount released from the FGF9-loaded PEA fibers after 24 h) as illustrated in Figure 3-8A,
suggesting that the FGF9 exogenously supplemented to PEA fibers is equivalent to the
released FGF9 from the loaded PEA fibers. Thus, the FGF9 exogenously supplemented
PEA fibers were selected to map the effective FGF9 concentration required for PDGFRβ
upregulation, for future loading into the PEA fibers. Consequently, the effect of FGF9
concentration on PDGFRβ gene expression was further studied in different cells (NIH-3T3,
10T1/2, and HCASMCs) seeded on control (TCPS) and PEA fibers with exogenous soluble
FGF9 of different concentrations (0, 8, 25 and 50 ng/mL). The q-PCR data showed
significant upregulation in the PDGFRβ expression at the lowest tested FGF9
concentration (8 ng/mL) for NIH-3T3 and 10T1/2 cells (Figure 3-8 B and C). In contrast,
the highest tested FGF9 concentration (50 ng/mL) was the concentration that resulted in
significant upregulation in the case of HCASMCs (Figure 3-8 D). Recent studies have
shown that pre-treatment of SMCs with FGF9 (100 ng/ml) for 24 h was found to increase
their chemotactic response to PDGF-BB [40], which is a ligand for PDGFRβ and a growth
factor necessary for mural cell recruitment during development and can promote vascular
stability [41]. As well, there was substantial increase in PDGFRβ expression in SMC preexposed to increasing concentrations of FGF9 (10 - 100 ng/mL) [12]. Furthermore, when
a PDGFRβ blocking antibody was added to angiogenic implants, it did not affect their
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vascularity after 2 weeks but reduced the number of vessels invested by mural cells
expressing smooth muscle α-actin [12]. The current findings support the premise that FGF9
is a regulator of PDGFRβ expression, which is the receptor necessary for FGF9-induced
mural cell recruitment, and that the critical concentration of FGF9 varies between mouse
fibroblasts, 10T1/2 cells, and human smooth muscle cells. This study may provide
important platforms for therapeutic angiogenesis and tissue engineering applications.

Figure 3-8: (A) Quantitative real-time PCR analysis of PDGFR-ß expression for
NIH-3T3 cells seeded on FGF9-loaded emulsion electrospun fibers and PEA fibers
with exogenous FGF9 for 24 h.
The effect of FGF9 concentration gradient on PDGFR-ß gene expression in (B) NIH-3T3
fibroblasts, (C) 10T1/2 cells, and (D) HCASMCs, seeded on TCPS (control) and PEA
fibers with exogenous FGF9 for 24 h. Data represents mean ± SEM, * indicates p < 0.05
and ** indicates p < 0.01 (n=3).
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Conclusions
Biodegradable poly(ester amide) fibers were successfully fabricated using electrospinning
techniques. Bead-free fibers of mean fiber diameter ~250 nm and uniform fiber diameter
distribution were produced using a binary solvent system of chloroform and DMSO (9:1).
PEA electrospun fibers preserved their fibrous structure over the four-week in vitro
degradation study in PBS (pH 7.4) and conditioned smooth muscle cell growth medium at
37 °C. Loaded PEA fibers exhibited controlled-release of BSA and FGF9 over 28 days
with a limited burst effect for both blend and emulsion electrospun fibers and preserved
FGF9 bioactivity. Moreover, the FGF9-loaded PEA elecrospun fibers were found to
maintain the metabolic activity of mouse fibroblasts for up to five days. Finally, q-PCR
analysis suggests that FGF9 is a stimulator of PDGFRβ expression, which is the receptor
necessary for FGF9-induced mural cell recruitment and vessel maturation. This data
supports the premise of FGF9 sustained delivery from PEA electrospun fibers and its
potential application in therapeutic angiogenesis and regenerative medicine. Future work
is required to examine dual loading of angiogenic growth factors and evaluating the
induced angiogenesis in vitro and in vivo.

References
1.

Dragneva, G., P. Korpisalo, and S. Yla-Herttuala, Promoting blood vessel growth
in ischemic diseases: challenges in translating preclinical potential into clinical
success. Dis Model Mech, 2013. 6(2): 312-22.

2.

Lusis, A.J., Atherosclerosis. Nature, 2000. 407(6801): 233-41.

3.

Lee, K.Y., M.C. Peters, and D.J. Mooney, Comparison of vascular endothelial
growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. J
Control Release, 2003. 87(1-3): 49-56.

4.

Said, S.S., J.G. Pickering, and K. Mequanint, Advances in growth factor delivery
for therapeutic angiogenesis. J Vasc Res, 2013. 50(1): 35-51.

5.

Sahoo, S., L.T. Ang, J.C.-H. Goh, and S.-L. Toh, Growth factor delivery through
electrospun nanofibers in scaffolds for tissue engineering applications. J Biomed
Mater Res, 2010. 93A: 1539–1550.
73

6.

Yang, Y., T. Xia, W. Zhi, L. Wei, J. Weng, C. Zhang, and X. Li, Promotion of skin
regeneration in diabetic rats by electrospun core-sheath fibers loaded with basic
fibroblast growth factor. Biomaterials, 2011. 32(18): 4243-54.

7.

Seyednejad, H., W. Ji, F. Yang, C.F. van Nostrum, T. Vermonden, J.J. van den
Beucken, W.J. Dhert, W.E. Hennink, and J.A. Jansen, Coaxially electrospun
scaffolds based on hydroxyl-functionalized poly(epsilon-caprolactone) and loaded
with VEGF for tissue engineering applications. Biomacromolecules, 2012. 13(11):
3650-60.

8.

Roy, R.S., B. Roy, and S. Sengupta, Emerging technologies for enabling
proangiogenic therapy. Nanotechnology, 2011. 22(49): 494004.

9.

Rubanyi, G.M., Angiogenesis in health and disease: Basic mechanisms and clinical
applications. 2000, New york: Marcel Dekker Inc.

10.

Agrotis, A., P. Kanellakis, G. Kostolias, G. Di Vitto, C. Wei, R. Hannan, G.
Jennings, and A. Bobik, Proliferation of neointimal smooth muscle cells after
arterial injury. Dependence on interactions between fibroblast growth factor
receptor-2 and fibroblast growth factor-9. J Biol Chem, 2004. 279(40): 42221-9.

11.

Spicer, D., FGF9 on the move. Nat Genet, 2009. 41(3): 272-3.

12.

Frontini, M.J., Z. Nong, R. Gros, M. Drangova, C. O'Neil, M.N. Rahman, O.
Akawi, H. Yin, C.G. Ellis, and J.G. Pickering, Fibroblast growth factor 9 delivery
during angiogenesis produces durable, vasoresponsive microvessels wrapped by
smooth muscle cells. Nat Biotechnol, 2011. 29(5): 421-427.

13.

Richardson, T.P., M.C. Peters, A.B. Ennett, and D.J. Mooney, Polymeric system
for dual growth factor delivery. Nat Biotechnol, 2001. 19(11): 1029-34.

14.

Knight, D.K., E.R. Gillies, and K. Mequanint, Strategies in Functional Poly(ester
amide) Syntheses to Study Human Coronary Artery Smooth Muscle Cell
Interactions. Biomacromolecules, 2011. 12(7): 2475-87.

15.

Vert, M., S. Li, and H. Garreau, New insights on the degradation of bioresorbable
polymeric devices based on lactic and glycolic acids. Clinical materials, 1992.
10(1-2): 3-8.

16.

Szentivanyi, A., T. Chakradeo, H. Zernetsch, and B. Glasmacher, Electrospun
cellular microenvironments: Understanding controlled release and scaffold
structure. Adv Drug Deliv Rev, 2011. 63(4-5): 209-20.

17.

Li, L. and C.C. Chu, Nitroxyl radical incorporated electrospun biodegradable
poly(ester Amide) nanofiber membranes. J Biomater Sci Polym Ed, 2009. 20(3):
341-61.

74

18.

Srinath, D., S. Lin, D.K. Knight, A.S. Rizkalla, and K. Mequanint, Fibrous
biodegradable l-alanine-based scaffolds for vascular tissue engineering. J Tissue
Eng Regen Med, 2012. 8(7): 578-588.

19.

del Valle, L.J., M. Roa, A. Díaz, M.T. Casas, J. Puiggalí, and A. Rodríguez-Galán,
Electrospun nanofibers of a degradable poly(ester amide). Scaffolds loaded with
antimicrobial agents. Journal of Polymer Research, 2012. 19(2): 1-13.

20.

Morgan, P.W., Interfacial Polymerization, in Encyclopedia of Polymer Science and
Technology. 2002, John Wiley & Sons, Inc.

21.

Pham, Q.P., U. Sharma, and A.G. Mikos, Electrospinning of polymeric nanofibers
for tissue engineering applications: a review. Tissue Eng, 2006. 12(5): 1197-211.

22.

Zong, X., K. Kim, D. Fang, S. Ran, B.S. Hsiao, and B. Chu, Structure and process
relationship of electrospun bioabsorbable nanofiber membranes. Polymer, 2002.
43(16): 4403-4412.

23.

Jarusuwannapoom, T., W. Hongrojjanawiwat, S. Jitjaicham, L. Wannatong, M.
Nithitanakul, C. Pattamaprom, P. Koombhongse, R. Rangkupan, and P. Supaphol,
Effect of solvents on electro-spinnability of polystyrene solutions and
morphological appearance of resulting electrospun polystyrene fibers. European
Polymer Journal, 2005. 41(3): 409-421.

24.

Tsitlanadze, G., M. Machaidze, T. Kviria, N. Djavakhishvili, C.C. Chu, and R.
Katsarava, Biodegradation of amino-acid-based poly(ester amide)s: in vitro weight
loss and preliminary in vivo studies. J Biomater Sci Polym Ed, 2004. 15(1): 1-24.

25.

Zamani, M., M. Morshed, J. Varshosaz, and M. Jannesari, Controlled release of
metronidazole benzoate from poly epsilon-caprolactone electrospun nanofibers for
periodontal diseases. Eur J Pharm Biopharm, 2010. 75(2): 179-85.

26.

Zeng, J., L. Yang, Q. Liang, X. Zhang, H. Guan, X. Xu, X. Chen, and X. Jing,
Influence of the drug compatibility with polymer solution on the release kinetics of
electrospun fiber formulation. J Control Release, 2005. 105(1-2): 43-51.

27.

Maretschek, S., A. Greiner, and T. Kissel, Electrospun biodegradable nanofiber
nonwovens for controlled release of proteins. J Control Release, 2008. 127(2): 1807.

28.

Sy, J.C., A.S. Klemm, and V.P. Shastri, Emulsion as a Means of Controlling
Electrospinning of Polymers. Advanced Materials, 2009. 21(18): 1814-1819.

29.

Yang, Y., X. Li, S. He, L. Cheng, F. Chen, S. Zhou, and J. Weng, Biodegradable
ultrafine fibers with core–sheath structures for protein delivery and its optimization.
Polym Adv Technol, 2011. 22(12): 1842-1850.

75

30.

Ritger, P.L. and N.A. Peppas, A simple equation for description of solute release I.
Fickian and non-fickian release from non-swellable devices in the form of slabs,
spheres, cylinders or discs. J Control Release, 1986. 5(1): 23-36.

31.

Baker, S.C. and J. Southgate, Towards control of smooth muscle cell differentiation
in synthetic 3D scaffolds. Biomaterials, 2008. 29(23): 3357-66.

32.

Naruo, K., C. Seko, K. Kuroshima, E. Matsutani, R. Sasada, T. Kondo, and T.
Kurokawa, Novel secretory heparin-binding factors from human glioma cells (gliaactivating factors) involved in glial cell growth. Purification and biological
properties. J Biol Chem, 1993. 268(4): 2857-64.

33.

Rubin, J.S., A.M. Chan, D.P. Bottaro, W.H. Burgess, W.G. Taylor, A.C. Cech,
D.W. Hirschfield, J. Wong, T. Miki, and P.W. Finch, A broad-spectrum human
lung fibroblast-derived mitogen is a variant of hepatocyte growth factor.
Proceedings of the National Academy of Sciences, 1991. 88(2): 415-419.

34.

Richardson, W.J., E. Wilson, and J.E. Moore, Jr., Altered phenotypic gene
expression of 10T1/2 mesenchymal cells in nonuniformly stretched PEGDA
hydrogels. Am J Physiol Cell Physiol, 2013. 305(1): C100-10.

35.

Horwitz, J.A., K.M. Shum, J.C. Bodle, M. Deng, C.C. Chu, and C.A. ReinhartKing, Biological performance of biodegradable amino acid-based poly(ester
amide)s: Endothelial cell adhesion and inflammation in vitro. J Biomed Mater Res
A, 2010. 95(2): 371-80.

36.

Deng, M., J. Wu, C.A. Reinhart-King, and C.C. Chu, Biodegradable functional
poly(ester amide)s with pendant hydroxyl functional groups: synthesis,
characterization, fabrication and in vitro cellular response. Acta Biomater, 2011.
7(4): 1504-15.

37.

Lin, S., M. Sandig, and K. Mequanint, Three-dimensional topography of synthetic
scaffolds induces elastin synthesis by human coronary artery smooth muscle cells.
Tissue Eng Part A, 2011. 17(11-12): 1561-71.

38.

Carlson, A.L., C.A. Florek, J.J. Kim, T. Neubauer, J.C. Moore, R.I. Cohen, J. Kohn,
M. Grumet, and P.V. Moghe, Microfibrous substrate geometry as a critical trigger
for organization, self-renewal, and differentiation of human embryonic stem cells
within synthetic 3-dimensional microenvironments. Faseb J, 2012. 26(8): 3240-51.

39.

Zhou, L., Y. Takayama, P. Boucher, M.D. Tallquist, and J. Herz, LRP1 Regulates
Architecture of the Vascular Wall by Controlling PDGFRÎ²-Dependent
Phosphatidylinositol 3-Kinase Activation. PLoS ONE, 2009. 4(9): e6922.

40.

Hellstrom, M., M. Kalen, P. Lindahl, A. Abramsson, and C. Betsholtz, Role of
PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and
pericytes during embryonic blood vessel formation in the mouse. Development,
1999. 126(14): 3047-55.
76

41.

Zhang, H., X. Jia, F. Han, J. Zhao, Y. Zhao, Y. Fan, and X. Yuan, Dual-delivery of
VEGF and PDGF by double-layered electrospun membranes for blood vessel
regeneration. Biomaterials, 2012. 34(9): 2202-12.

77

Chapter 4
4

Concurrent and Sustained Delivery of FGF2 and FGF9 from

Electrospun Poly(ester amide) Fibrous Mats for Therapeutic
Angiogenesis
Overview: This chapter discusses the dual loading of the PEA electrospun fibers with
FGF2 and FGF9 using a mixed blend and emulsion electrospinning technique, and studies
the effect of the dual-loaded PEA electrospun fibrous scaffolds on endothelial cell tube
formation and directed smooth muscle cell migration. Moreover, it investigates the
inflammatory host response in vitro using THP-1 human monocytes and in vivo by
subcutaneous implantation into B6 mice.

Abstract
Therapeutic angiogenesis has emerged as a potential strategy to treat ischemic vascular
diseases. However, systemic or local administration of growth factors is usually inefficient
for maintaining the effective concentration at the site of interest due to their rapid clearance
or degradation. In this study, a differential and sustained release of an angiogenic factor;
fibroblast growth factor-2 (FGF2), and an arteriogenic factor; fibroblast growth factor-9
(FGF9), from α-amino acid-derived biodegradable poly(ester amide) (PEA) fibers was
reported towards targeting neovessel formation and maturation. FGF2 and FGF9 were
dual-loaded using a mixed blend and emulsion electrospinning technique, and exhibited
differential and sustained-release from PEA fibers over 70 days with preserved bioactivity.
In vitro angiogenesis assays showed enhanced endothelial cell (EC) tube formation and
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directed-migration of smooth muscle cells (SMCs) to PDGF-BB, and stabilized EC/SMC
tube formation. FGF2/FGF9-loaded PEA fibers did not induce inflammatory responses in
vitro using human monocytes or in vivo after their subcutaneous implantation into mice.
Histological examination showed that FGF2/FGF9-loaded fibers induced cell niche
recruitment around the site of implantation. Furthermore, controlled in vivo delivery of
FGF9 to mouse tibialis anterior muscle resulted in a dose-dependent expansion of
mesenchymal progenitor cell-like layers and ECM deposition. The data suggests that the
release of FGF2 and FGF9 from PEA fibers offers an efficient differential and sustained
growth factor-delivery strategy with relevance to therapeutic angiogenesis.
Keywords: Electrospinning; Fibroblast growth factor-2; Fibroblast growth factor-9;
Poly(ester amide)s; Therapeutic angiogenesis.

Introduction
Therapeutic angiogenesis, the induction of new blood vessel formation, has emerged as a
potential approach to treat ischemia caused by coronary and peripheral arterial diseases [1].
A fundamental component of regenerative medicine is neovascularisation, which can be
induced by promoting expression of angiogenic genes or targeted delivery of angiogenic
growth factors and progenitor cells via engineered materials [2]. Although angiogenic
protein therapy is the simplest and most straightforward approach for therapeutic
angiogenesis, systemic administration of angiogenic factors is usually inefficient for
reaching and/or maintaining the desired effective concentration at the site of interest due
to rapid clearance or degradation of the delivered protein [3, 4]. Local administration (e.g.
intracoronary, intramyocardial, or intracerebral injection) can better confine the
distribution of the growth factors at the desired site; however, it requires expensive pumps
or invasive surgeries [5]. Recently, biomimetic nanofibers have become auspicious
candidates for delivering bioactive molecules, promoting a viable approach for local and
controlled delivery of angiogenic factors to overcome the aforementioned challenges [69].
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Neovessel formation and maturation requires the precise spatiotemporal presentation of
both angiogenic and arteriogenic growth factors, so that endothelial tubes can form and
recruit mural cells for subsequent investment of these nascent vessels with perivascular
cell coverage, which is essential for stable blood vessel formation [10, 11]. FGF2 is one of
the most extensively studied angiogenic factors in therapeutic angiogenesis [12-15].
However, clinical studies of FGF2 showed short-term induced angiogenesis as the new
microvessels regressed over time and therefore did not confer long-term improvements in
tissue perfusion [16, 17]. This is probably due to quick inactivation of FGF2 with bolus
delivery, issues with patient selection and clinical trial end points [18], and the generation
of immature and unstable blood vessels that regressed over time [9, 19]. Unlike FGF2,
FGF9 is not angiogenic but it is known to target the mesenchyme [20], and to elevate
neointimal smooth muscle cell proliferation after arterial injury [21]. Previously, the
combination of FGF2 and FGF9 was shown to stimulate the formation of robust
microvessels in Matrigel plugs that are more likely to persist compared with using only
FGF2, and had the ability to respond to vasoactive agents [22]. In an ischemic hind limb
mouse model, vessels formed in the presence of FGF9, delivered by means of an osmotic
pump, were physiologically mature due to smooth muscle migration that wrapped the
nascent microvessels resulting in their stabilization [22]. Notwithstanding this encouraging
data, the use of an osmotic/infusion pump was accompanied by induced inflammation and
is not clinically practical. Therefore, differential delivery of these growth factors in a pumpfree controlled and sustained manner remains to be an immediate need.
In order to protect the growth factors from rapid clearance and to target neovessel
maturation, the proposed strategy is to differentially deliver angiogenic (FGF2) and
arteriogenic (FGF9) growth factors from a single electrospun biomaterial system. The
differential delivery of this new combination of growth factors is promising; since FGF2
will be released at a higher rate in the early stage inducing vessel formation, while FGF9
will be released at a lower rate recruiting mural cells at a later stage prompting vessel
stabilization. Different laboratories reported the release of two or more growth factors from
composite biomaterial delivery systems where growth factors were loaded in different
polymers and then combined to form a composite system [23-26]. It would be more
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practical if differential release is attained from only one biomaterial; but this is challenging
owing to the bulk degradation properties of most biomaterials. Vascular endothelial growth
factor (VEGF) and platelet derived-growth factor (PDGF) has been a very popular
combination and their dual delivery was widely investigated for blood vessel regeneration
[8, 23, 27]; however, it has been reported that VEGF can act as a negative regulator for
pericyte coverage of vascular sprouts through VEGFR-2 and consequently hinder vessel
maturation under the conditions of PDGF-mediated angiogenesis [28].
In the current study, α-amino acid derived poly(ester amide) (PEA) electrospun fibers were
proposed as a versatile controlled delivery vehicle for FGF2 and FGF9 to target
neovascular maturation. PEAs derived from α-amino acids were previously shown to
degrade by surface erosion mechanism and were biocompatible for tissue engineering
applications [29-31]. Following a proof of principle study on the feasibility of
biodegradable α-amino acid derived PEA nanofibers to deliver FGF9 [32], the objectives
of the current study were three-fold: (i) to dual load FGF2 and FGF9 into PEA fibers using
a mixed blend and emulsion electrospinning technique and study the morphological
properties and the in vitro dual release kinetics, (ii) to examine the in vitro angiogenesis
capacities of the co-released FGF2 and FGF9 using endothelial tube formation and directed
smooth muscle cell migration assays and, (iii) to evaluate the in vitro and in vivo
inflammatory responses and potential cell niche recruitment.

Materials and Methods
4.3.1

Materials

The poly(ester amide) 8-Phe-4 was synthesized from L-phenylalanine, sebacoyl chloride,
and 1,4-butanediol via interfacial polymerization and characterized as described in
previous publications [29, 32]. Bovine serum albumin (BSA) and Fibronectin were
purchased from Sigma-Aldrich Canada Co. (Oakville, ON). Micro BCA protein assay kit
from Thermo Scientific Pierce Inc. (Rockford, IL). Recombinant human fibroblast growth
factor-9 (FGF9), fibroblast growth factor-2 (FGF2), Platelet–derived growth factor BB
(PDGF-BB), and human FGF9 and FGF2 DuoSet® ELISA kit were purchased from R&D
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Systems Inc. (Minneapolis, MN). Vybrant® DiI and Hoechst 33342 dyes were from Life
technologies (Burlington, ON).

4.3.2

Cell Culture and Maintenance

Primary human coronary artery smooth muscle cells (HCASMCs) were purchased from
Lonza (Walkersville, MD) and cultured according to the supplier’s instructions in Medium
231 and Smooth muscle growth supplement, complemented with 100 units/ml penicillin G
sodium, 100 µg/ml streptomycin sulphate, and 2 mM L-glutamine (Invitrogen, Burlington,
ON). Primary human coronary artery endothelial cells (HCAECs) were purchased from
Lonza (Walkersville, MD) and cultured according to supplier’s instructions in EGM–MV
Bullet Kit (Lonza, Walkersville, MD). THP-1 human monocytes (ATCC® TIB202™) were
cultured in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% FBS, and 1%
penicillin/streptomycin (Invitrogen, Burlington, ON). All cultures were maintained in a
humidified chamber at 37ºC containing 5% CO2. Cells were passaged every 7 days at a
split ratio of 1:3 and used between passages 6 to 8.

4.3.3

Dual-loading of PEA Fibers

Dual loading of model protein BSA or FGF2, and FGF9 into the PEA fibers was carried
out using a mixed technique of blend and emulsion electrospinning. The electrospinning
parameters were established in previous studies [32]. Briefly, the PEA (8-Phe-4, average
number MW between 30-40 kDa) was dissolved in chloroform and dimethyl sulfoxide
(DMSO) at a ratio of (9:1). The polymer solution (0.5 mL) at 7.5% w/w concentration was
electrospun using a high voltage DC power supply (ES30P, Gamma high voltage, USA)
set to 20 kV and a 0.5 cc glass syringe (Becton, Dickinson and Co., Franklin Lakes, NJ)
with a blunt–tip stainless steel spinneret (22 gauge) kept at 8 cm from the grounded
collector (a rotating mandrel covered with aluminum foil rotating at 1000 rpm). The flow
rate was kept at 0.1 mL/h using a syringe pump (KD101, KD scientific, Holliston, MA).
BSA was dissolved in DMSO (1 µg/µL) and 100 µL were blended in the polymer solution.
The same protocol was adopted for FGF2 loading, except for the lower initial loading (3.6
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µg FGF2 per 100 µL of DMSO). Whereas, 30 µL of stock FGF9 solution in PBS (120
ng/µL) were emulsified in the polymer solution by ultrasonication for 30 min in an ice
bath. Similarly, Vybrant® DiI and Hoechst 33342 dyes were dual-loaded into the PEA
fibers following the same procedure as FGF2 and FGF9, respectively.

4.3.4

Characterization of PEA Electrospun Fibers

Morphological analysis of the PEA fibers was performed using scanning electron
microscopy and confocal laser scanning microscopy. For SEM, electrospun fibrous mat
samples were sputter–coated with gold/palladium (K550X sputter coater, Emitech Ltd.,
UK) and scanned at a working distance of 10 mm and a constant accelerating voltage of 20
kV, using S–3400N SEM (Hitachi, Japan). Vybrat® DiI and Hoechst dual loaded–PEA
fibers were electrospun on No.1 coverslips for 30 s. Another No.1 coverslip was mounted
over the coverslip containing the fibers and Trevigen® Fluorescence Mounting Medium
(Trevigen INC., Gaithersburg, MD), and confocal images of Vybrat® DiI and Hoechst dual
loaded–PEA fibers were captured with a Zeiss LSM 5 Duo confocal microscope equipped
with nine laser lines and appropriate filters (Carl Zeiss, Toronto, ON).

4.3.5

In vitro Release Study of Dual-loaded PEA Electrospun Fibers

In vitro release studies of dual loaded PEA fibers were conducted as described previously
for FGF9-loaded fibers [32]. Samples of 1 cm × 1 cm fibrous mats (with total amount of 4
µg of BSA or 120 ng FGF2, and 120 ng FGF9/mat) were placed in a 24–well plate, and
incubated with 1 mL of phosphate–buffered saline (PBS 50 mM, pH 7.4) under continuous
agitation (100 strokes/min), in a thermostatically controlled micro–plate shaker (VWR
International, Mississauga, ON) at 37°C. At pre–determined time intervals (Day 1, 3, 7,
10, 14, and weekly thereafter), the supernatant was collected and replenished with an equal
volume of fresh buffer. The supernatants were immediately frozen at −80°C until further
measurements. The amount of BSA released was quantified by micro BCA protein assay
kit, while the amount of FGF2 and FGF9 released was quantified by DuoSet® ELISA assay
kit. The absorbance was measured using a micro–plate reader (UVM 340, Montreal
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Biotech Inc., QC) and the unknown concentration was determined from a pre–constructed
calibration curve and the percentage entrapment efficiency data. In order to correlate the
in vitro release of the growth factors to the degradation rate of the PEA fibers; in vitro
degradation of (1 cm × 1 cm) dual-loaded PEA mats was studied in PBS (50 mM, pH 7.4)
at 37 °C for 3 months and evaluated by % mass loss and molecular weight analysis as
previously described [32].

4.3.6

In vitro Angiogenesis Assays: Matrigel Tube Formation Assay

Cell viability and metabolic activity of HCAECs on the 3D FGF2/FGF9-loaded PEA fibers
was determined for 5 days by MTT assay following the manufacturer’s protocol
(Vybrant®, Invitrogen, Burlington, ON, Canada). Unloaded fibers supplemented with
soluble FGF2 and FGF9 was included as a positive control, and TCPS as a negative control.
The experiments were conducted in triplicate as previously described [32]. Evaluation of
in vitro tube formation using Matrigel assay was conducted by means of digital time–lapse
video microscopy [33]. FGF2/FGF9–loaded fibers were allowed to release the growth
factors in 35 mm culture dishes containing EC culture media (EGM-MV BulletKit, Lonza)
for 7 days, in an incubator at 37°C and 5% CO2; 1 cm × 1 cm mats were utilized with total
amount of 120 ng FGF2 and 120 ng FGF9/mat. 200–µL aliquots of the growth factor–
reduced Matrigel (VWR International, Mississauga, ON) were added per well to a 24-well
plate and allowed to polymerize at 37°C for 30 min. HCAECs were trypsinized then
suspended in a 250 µL media containing the released FGF2 and FGF9, and seeded at a
density of 75,000 cells/well on Matrigel for 4 days. Images were acquired on an Olympus
IX51 inverted microscope, using a 10× objective. The numbers of tube branch points were
counted for two fields of view per well for different time points. Culture media incubated
with unloaded PEA fibers served as a negative control, whereas media supplemented with
FGF2 and FGF9, equivalent to that released at 7 days from the loaded fibers calculated
from the in vitro release data, served as a positive control. Each treatment was performed
in duplicate and three independent experiments were conducted.
A modified tube formation assay was adopted in order to evaluate the interaction between
endothelial cells and smooth muscle cells. To do this, HCAECs were infected with 30 µL
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of Red Fluorescent Protein-Adenovirus (RFP-Adenovirus)/10 mm dish, while HCASMCs
were infected with 100 µL of Green Fluorescent Protein-Adenovirus (GFPAdenovirus)/10 mm dish for 48 h. Tube formation assay protocol was followed as
mentioned above and after 5 h incubation of RFP-expressing HCAECs on the Matrigel,
GFP-expressing HCASMCs were added at 75,000 cells/well and incubated for further 24 h
to evaluate SMC-interaction with the endothelial tubes using digital time–lapse video
microscopy. Images were acquired, using a 10× objective, every 30 min for 24 h on Leica
DMi8 inverted fluorescent microscope integrated with LAS-AF lite 2.6 software (Leica
Microsystems Inc., Concord, ON).

4.3.7

Directed Human Coronary Artery Smooth Muscle Cell Migration Assay

Directed vascular smooth muscle cell migration was assessed by the transwell migration
assay [34], using a Boyden–type microchemotaxis chamber (Neuro Probe, Inc.,
Gaithersburg, MD). HCASMCs were treated with FGF2/FGF9–loaded fibers for 7 days.
HCASMCs were seeded onto 35 mm tissue culture dishes at cell density of 100,000
cells/dish. The cells were allowed to attach for 1 h in the incubator, and then the 1 cm × 1
cm FGF2/FGF9-loaded mat was suspended in the dish. The dual-loaded mats were allowed
to release both FGF2 and FGF9 over 6 days (the SMC culture media containing 10% FBS
was refreshed every other day). On Day 6, HCASMCs were starved for 24h by refreshing
with serum–depleted media (containing 2% FBS). Polycarbonate membranes (Neuro
Probe, Inc., Gaithersburg, MD) with 10 μm pores were pre–coated with 10µg/mL
fibronectin and kept at 4°C overnight. Untreated or FGF2/FGF9–treated SMCs were
washed in HBSS, trypsinized, and 25,000 cells re–suspended in 50 µL of serum–depleted
media were added to the upper well of the Boyden chamber. The lower well of the chamber
was filled with 28 µL of serum–depleted media with or without the chemotactic agent
PDGF–BB. Migration was allowed to proceed for 6 h at 37°C under 5% CO2. SMCs
remaining on the upper surface of the membrane (non-migrated cells) were mechanically
removed using a wiper blade after dipping in PBS, and then the membrane was fixed in
methanol (for 5 min) and stained with Harris’s hematoxylin (for 10 min). The number of
cells that had migrated to the lower surface was determined by counting under high–power
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microscopy (40× objective) in eight fields of view per well using an Olympus BX51
inverted microscope. The experiments were performed in triplicate, and positive controls
of soluble FGF2/FGF9–treated SMCs were included in the experiment. Moreover, this
assay was used to test the bioactivity of the early released (cumulative released FGF2 and
FGF9 between Day 1 and Day 13) and late released (cumulative released FGF2 and FGF9
between Day 14 and Day 28) growth factors from the dual loaded PEA fibers, collected
during the in vitro release study.

4.3.8

In vitro Gene Expression of the Inflammatory Marker (Interleukin 8)

Unloaded and FGF9/FGF2–loaded PEA fibers were affixed to the bottom of 12–well plate,
sterilized by immersion in 70% ethanol (200 µL) for 30 min, and allowed to dry for one
hour under germicidal UV light, before conditioning overnight in Hank’s balanced salt
solution (HBSS, 200 µL; Invitrogen, Burlington, ON). THP-1 human monocytes were
seeded onto the samples at an initial cell density of approximately 2 × 105 cells/well and
cultured for three days in RPMI 1640 media containing 10% FBS, 1%
penicillin/styptomycin and 2 mM L–glutamine, and maintained in a humidified incubator
at 37 °C and 5% CO2. Negative controls (TCPS), and positive controls of cells incubated
with Escherichia coli lipopolysaccharide (E. coli LPS) at concentration of 5 µg/mL, were
included in the experiment. After 72 h, the cells were collected and total RNA was
extracted following TRIzol® reagent manufacturer’s protocol for suspended cells, and
quantitative real-time Polymerase Chain Reaction (RT-qPCR) assay was employed to
evaluate the RNA expression of the inflammatory marker interleukin 8 (IL-8) [35].

4.3.9

RNA Isolation and Quantitative Real–time PCR Analysis

qPCR combined with reverve transcription was used to quantify messenger RNA (mRNA)
expression of IL–8 in THP–1 cells seeded on control (TCPS), incubated with a positive
control of E. coli lipopolysaccharide (E. coli LPS), unloaded PEA fibers, and FGF2/ FGF9–
loaded PEA fibers. Total RNA from the cells was extracted using TRIzol® reagent
(Invitrogen, Burlington, ON) following the manufacturer’s protocol. Complementary DNA
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(cDNA) was synthesized using 1µg of total RNA primed with oligo12–18 as described in
SuperScript™ (Invitrogen, Burlington, ON). qPCR was conducted in 10 µl reaction
volumes, using a CFX–96 Touch™ Real–time system C1000 Thermal Cycler (Bio–Rad,
Mississauga, ON) and gene expressions of human IL–8 was then determined with
SsoAdvanced™ SYBR® Green Supermix (Bio–Rad) according to the recommended
protocol

of

the

manufacturer.

5′– CTTCCTGATTTCTGCAGCTCT–3′,

IL–8

forward

reverse

5′– GTGGTCCACTCTCAATCACTC–3′,

GAPDH

5′– GGTGGTCTCCTCTGACTTCAACA–3′,

primer:
primer:

forward
reverse

primer:
primer:

5′– GTTGCTGTAGCCAAATTCGTTGT–3′. Amplification entailed 40 cycles of:
denaturation 95°C (15 s), annealing 55°C (30 s), and extension 65°C (30 s). The relative
mRNA expression in the cells was normalized to the housekeeping gene glyceraldehyde–
3–phosphate dehydrogenase (GAPDH) with at least three repeats per experimental group
and expressed as a relative ratio using the CFX ManagerTM 3.0 analysis software (Bio–
Rad, Mississauga, ON).

4.3.10

Implantation into Subcutaneous and Tibialis Anterior Muscle Tissues

The host response was evaluated by subcutaneously implanting unloaded and
FGF2/FGF9–loaded PEA fibrous mats in 8–week old male C57BL/6J mice (The Jackson
Laboratory, Bar Harbor, Maine). Experiments were conducted in accordance with the
University of Western Ontario Animal Use Subcommittee. Briefly, samples of (4 mm ×
4 mm) PEA fibrous mats, unloaded or dual-loaded with FGF2 and FGF9 with total amount
of 20 ng FGF2 and 20 ng FGF9/mat (n = 4), were surgically implanted into the dorsal
subcutaneous tissue just superficial to the skeletal muscle and were harvested after 6 days.
Prior to implantation, all the mats were sterilized under ultraviolet radiation for 4 h/each
side. The mice were anaesthetized with Forane® (Baxter, Deerfield, IL) and their backs
were shaved and wiped with alcohol. Two 6 mm horizontal full thickness skin incisions
were made and the unloaded PEA mat was inserted in the left incision while the growth
factor–loaded was implanted in the right incision and the incision was sutured using 6-0
silk sutures to retain the mat in place. Sham surgery was included in the experiment to
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serve as a control (n=2), where the incisions were made and sutured without the insertion
of the PEA mats. The mice were sacrificed after 6 days, and the mats with the attached
subcutaneous tissue were excised for histological examination. The tissue sections
collected from the mice were fixed in 4% paraformaldehyde and dehydrated in 70%
ethanol, then embedded in paraffin wax. Five micrometer–thick sections were cut with a
rotary microtome (Leica 5 micron microtome) and Hematoxylin and Eosin (H&E) stained.
H&E stained sections were examined with a Leica inverted light microscope (Leica
Microsystems Inc., Concord, ON) and investigated for the infiltration of inflammatory
cells. Follow-up experiments were carried out to evaluate the effect of FGF9 controlled
delivery from the PEA fibers, at different initial loading concentrations (0, 20, 40, and
80 ng/mat), on cell and tissue reaction upon implantation on the tibialis anterior muscle in
the hind limb of B6 mice. Seven days after implantation of the FGF9-loaded PEA fibers
onto the TA muscle, the mice were sacrificed and perfusion-fixed with 4%
paraformaldehyde. The anterior calf muscle bundle was dehydrated in 70% ethanol,
paraffin-embedded, and 5 μm sections were subjected to H&E staining and investigated
for cell niche recruitment.

4.3.11

Statistical Analysis

Data is presented as mean ± SEM for experiments conducted in triplicate. Statistical
analysis was conducted with one–way ANOVA followed by Tukey’s multiple comparison
test using GraphPad Prism 4 software (GraphPad Software, Inc., San Diego, CA).
Probability values less than 0.05 were considered statistically significant, unless otherwise
stated.

Results
4.4.1

Differential Release of FGF2 and FGF9 from Dual-loaded PEA Fibers

In previous work, successful loading of FGF9 into PEA fibers was reported using blend
and emulsion electrospinning techniques [32]. In the current study, a mixed blend and
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emulsion electrospinning technique was proposed for dual loading of FGF2 and FGF9 into
PEA fibers for therapeutic angiogenesis application. Confocal microscopy was employed
to examine the dual loading strategy using two model fluorescent dyes. Red Vybrant ® DiI
was loaded using blend electrospinning, while blue Hoechst 33342 was loaded using
emulsion electrospinning. The presence of blue vesicles along the red PEA fiber matrix
(Figure 4-1 A) confirms the success of the dual loading strategy for the two model dyes
using the mixed electrospinning technique.
To demonstrate the controlled and differential release of bioactive molecules, a model
protein (BSA, 4 µg/cm2) was dual-loaded with FGF9 (120 ng/cm2) into the PEA fibers.
The morphology of the fibers was investigated using SEM, showing bead–free fibers with
uniform fiber diameter distribution (Figure 4-1 B inset). The in vitro release of BSA and
FGF9 was sustained over the 4 weeks study, in PBS (pH 7.4) at 37 °C, reaching
approximately 76.9% and 25.3% for BSA and FGF9, respectively after 28 days (Figure 4-1
B). In the same way, FGF2 (120 ng/cm2) and FGF9 (120 ng/cm2) were dual loaded into the
PEA fibers. Similar sustained and differential release profiles were attained, which were
fitted to a time–dependent power–law function [36]. The amount of FGF2 and FGF9
released from the PEA fibers at the end of the 4–week study was approximately 28.5% and
19.4%, respectively (Figure 4-1 C). Release studies for longer time periods (70 days), also
showed a continuous controlled release of the growth factors reaching about 54.2% for
FGF2 and 40.7% for FGF9 (Figure 4-1 C). In vitro degradation of the PEA fibers was
previously investigated in PBS (pH 7.4) at 37°C for 4 weeks [32], and the fibrous mats
maintained their structural integrity with total percentage mass loss of 21% after 28 days
and without significant change in molecular weight. Longer degradation time-points
showed 48% mass loss after 84 days while the molecular weight did not change appreciably
indicating surface erosion degradation mechanism, which matches the in vitro release data
(Figure 4-1 D-E). This supports the idea that biodegradable PEA fibers could be utilized in
sustained co-delivery of FGF2 and FGF9 while attaining a differential release of the dualloaded growth factors.
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Figure 4-1: Combined blend and emulsion electrospinning of growth factors facilitate
differential release of the loaded proteins.
(A) Confocal microscopy images of DiI and Hoechst dyes dual-loaded PEA fibers
following the same mixed electrospinning protocol for growth factor loading. In vitro
release study of (B) BSA and FGF9, (C) FGF2 and FGF9 dual-loaded PEA fibers, in PBS
pH 7.4 at 37 °C for 4 weeks (n=3), with corresponding SEM insets, scale bar = 2 µm. In
vitro degradation of PEA electrospun fibers in PBS (pH=7.4) at 37°C for 84 days. (D)
Percentage mass loss of PEA fibers at different time points (n=3) and (E) molecular weight
analysis using gel permeation chromatography.
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4.4.2
Co-released FGF2 and FGF9 from PEA Fibers Enhanced Tube
Formation and Directed SMC Migration
The MTT metabolic activity assay showed that the number of attached human coronary
artery endothelial cells (HCAECs) at Day 1 on both dual-loaded and unloaded fibres
supplemented with FGF2 and FGF9 were fewer than those on the TCPS control (Figure
4-2 ). However, those attached cells were viable for up to 5 days. Since visualization of
tube formation on the 3D fibers/Matrigel via microscopy is not feasible due to the nontransparency of the fibers, tube formation was investigated using a Matrigel tube formation
assay employing HCAECs treated with media containing the co-released FGF2 and FGF9.
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Figure 4-2: Human coronary artery endothelial metabolic activity study on 3D
FGF2/FGF9-loaded PEA fibers, unloaded fibers supplemented with soluble FGF2
and FGF9 as a positive control, and TCPS as a negative control, for 5 days using MTT
assay. Data represents mean ± SEM from three independent experiments.

Endothelial tubes formed after 24 h of incubation were visualized by optical microscopy
using a 10× objective (Figure 4-3). Quantitative representation of the data showed
significant increase in the number of tubule branch points at 24 h in the case of co-released
FGFs from the dual loaded PEA fibers compared to the negative control of culture media,
whereas there was no significant difference from the positive control of soluble FGF2 and
FGF9 (p < 0.05) as illustrated in Figure 4-3. Although the endothelial tubes would
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eventually regress, the endothelial tubes treated with the co-released FGFs were holding
better than the negative control after 4 days. This data supports that FGF2, being an
angiogenic growth factor, stimulates tube formation and proposes potential benefits of
strategically pairing it with FGF9.

Figure 4-3: Co-released FGF2 and FGF9 from PEA fibers increased endothelial cell
tube formation. Endothelial cells were treated with co-released FGFs or soluble FGF
and cultured on growth factor–reduced Matrigel for 24 h.
The tubule branch points were counted using an inverted microscope at 10× objective at
different time points (n=3). Fresh culture media and growth factor-supplemented media
were used as negative and positive controls, respectively. Scale bar = 200 µm, * indicates
p < 0.05.

A Boyden chamber transwell migration assay was employed to evaluate the directed
migration of FGF2/FGF9 treated–human coronary artery smooth muscle cells
(HCASMCs) to the chemotactic agent PDGF-BB. As illustrated in Figure 4-4 A-B, there
was a significant increase in the number of migrated SMCs in the presence of PDGF-BB
as a chemotactic agent compared to the group without PDGF-BB. This suggested that the
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migration of FGF2/FGF9-treated SMCs was dominated by active directed migration to
PDGF-BB instead of random migration. Also, the HCASMCs treated with the FGF2/FGF9
dual-loaded fibers for 7 days showed a significant increase in directed migration compared
to the negative control of untreated SMCs (p < 0.05). This indicated that FGF2/FG9
treated-SMCs were more attracted to PDGF-BB.
Ongoing research has shown the need of prolonged exposure of ischemic tissues to
angiogenic and arteriogenic growth factors for the development of robust and sustained
neovascularization [1, 18]. Since the ultimate goal is to use electrospun PEA fibers as a
depot for FGF2 and FGF9 for ischemic tissue repair, the bioactivity of the co-released
growth factors was evaluated over a period of 4 weeks. The data revealed that both early
(released between Day 1 and Day 14) and late released (released between Day 15 and
Day 28) growth factor–treated SMCs showed significant increase in the number of
migrated cells compared to that of the negative control (p < 0.01); while the difference with
their respective positive controls was not significant (p > 0.05; Figure 4-4 C-D). This
observation suggests that the released growth factors from the PEA fibers will be available
in a bioactive form for the period required to secure the stabilization and survival of the
newly formed vessels.
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Figure 4-4: Co-released FGF2 and FGF9 enhanced directed smooth muscle cell
migration.
(A and B) SMCs were incubated with FGF2/FGF9 dual loaded PEA fibers for 7 days and
the treated SMCs that had migrated to PDGF-BB, after 6 h of incubation in Boyden
chamber, were fixed, stained with Haematoxylin, and counted under high–power
microscopy (40× objective) (n=3). Darker dots represent the membrane pores and lighter
ones represent the nuclei. (C and D) Early co-released (Day 1 - Day 14; ER) and late coreleased (Day 15 - Day 28; LR) FGF2 and FGF9 from the PEA fibers from in vitro release
study. Negative control of untreated SMCs and positive control of FGF2/FGF9–treated
SMCs were included in the experiment. Scale bar = 100 µm, * indicates p < 0.05, **
indicates p < 0.01.

Neovessel maturation requires the recruitment of mural cells and the subsequent wrapping
of the nascent endothelial tubes with smooth muscle cells, which is essential for stable
blood vessel formation.

Tube formation assay protocol was used to evaluate SMC

interaction with the endothelial tubes using digital time–lapse video fluorescent
microscopy. GFP-expressing HCASMCs were attracted to the RFP-expressing HCAEC
tubes. After 24 h of incubation, SMCs invested the tube network of GFP-expressing
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endothelial cells on Matrigel; the SMCs were wrapping the EC tubes resulting in thicker
EC/SMC tubes when treated with the co-released FGF2 and FGF9 or soluble FGFs
compared to the negative control (Figure 4-5). This demonstrates that co-released FGF2
and FGF9 from the dual loaded PEA fibers can enhance the SMC-EC interaction and
stabilize tube formation in vitro.

Figure 4-5: Co-released FGF2 and FGF9 from dual-loaded PEA fibers stabilize tube
formation.
RFP-expressing endothelial cells were treated with co-released FGFs or soluble FGFs and
cultured on growth factor–reduced Matrigel and incubated for 5 h, followed by culturing
GFP-expressing smooth muscle cells at same cell density (75,000 cells/well) and further
incubation for 24 h. Images were acquired, using a 10× objective, every 30 min for 24 h
on Leica DMi8 inverted fluorescent microscope (n = 3). Negative control of fresh culture
media and positive control of soluble growth factor-supplemented media were included in
the experiment. Scale bar = 100 µm.
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4.4.3
FGF2 and FGF9 Dual-loaded PEA Fibers did not Induce Inflammatory
Responses
The utility of FGF2/FGF9-dual loaded PEA fibers for therapeutic angiogenic application
necessitates evaluating the induced inflammatory responses. For in vitro studies, human
monocytes (THP-1) were incubated with unloaded and FGF2/FGF9 dual-loaded PEA
fibers for 72 h, followed by evaluation of the RNA expression of a selected inflammatory
marker (IL-8) using quantitative real time PCR assay. Figure 4-6 shows that both unloaded
and dual-loaded PEA fibers did not show a significant difference in IL-8 gene expression
compared with the negative control tissue culture polystyrene (TCPS). On the other hand,
the E. coli LPS-treated human THP-1 monocytes (positive control) showed significant fold
increase in gene expression of IL-8 (p < 0.01). Therefore the lower RNA expression of
IL- 8, a cytokine known for its leukocyte chemotactic activity,[37] may lead to a lesser
leukocyte chemotaxis at the site of the PEA fibers implantation and this will lead to a
reduced host immune response [35].

Figure 4-6: FGF2/FGF9-loaded PEA electrospun fibers did not induce an
inflammatory response in vitro.
The gene expression of the inflammatory marker IL-8 was evaluated using quantitative
real-time PCR assay after incubation of the PEA fibrous mats with THP-1 monocytes for
72 h (n = 3). Positive control of E. coli lipopolysaccharide was included in the experiment,
** (p < 0.01).
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The in vivo tissue response was evaluated by implanting unloaded and growth factorloaded PEA fibrous mat subcutaneously at the back of 8–week male B6 mice for 6 days,
followed by the excision of the tissue and H&E staining for histological examination. H&E
histological sections of the unloaded and the FGF2/FGF9-dual loaded PEA fibers
demonstrated that the fibers did not fully degrade after 6 days of subcutaneous implantation
and did not stimulate inflammatory cell infiltration or induce scar formation (Figure 4-7).
Interestingly, in the case of the FGF2/FGF9-loaded PEA fibers; robust cell niche
recruitment was observed around the mat. Furthermore, the damaged connective tissue
started to regenerate around the fibers and there was higher population of cells resembling
mesenchymal progenitor cells with increased ECM secretion around the FGF2/FGF9-dual
loaded PEA fibrous mat.
FGF9-loaded PEA fibers were implanted onto the tibialis anterior muscle of B6 mice for 7
days in order to evaluate the effect of FGF9 controlled delivery from the PEA fibers, at
different initial loading concentration (0, 120, 240, 480 ng/cm2), on cell niche recruitment
in the context of hind limb muscles. Histological examination of the H&E sections
demonstrated that the unloaded PEA fibrous mat implantation resulted in the encapsulation
of inflammatory cells (Figure 4-8 A inset, red arrows). The induced inflammation was
diffusive, but limited to the area surrounding the hypodermis and muscle surface. On the
other hand, FGF9-loaded PEA fibrous mat implantation resulted in the amelioration of the
inflammatory reaction (Figure 4-8 B-D). More importantly, FGF9 loading resulted in a
dose-dependent expansion of mesenchymal progenitor-like cells that were organized in
layers and deposited extracellular matrix surrounding the fibrous mat, but did not invade
into the skin or the muscle. The highest tested initial FGF9-loading (480 ng/cm2) showed
the most distinct expansion of the matrix-depositing cells and their higher level
organization into layers (Figure 4-8 D inset, green brackets).
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Figure 4-7: Subcutaneous implantation of FGF2/FGF9-loaded PEA electrospun
fibers in B6 mice did not induce inflammatory cell infiltration.
Sham surgery and negative control of unloaded PEA fibers were included in the experiment
(n = 4). H&E histological sections were examined with a Leica inverted light microscope
for inflammatory cell infiltration. Blue arrows are pointing to the PEA fibers and
scale bar = 100 µm.
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Figure 4-8: Controlled delivery of FGF9 from PEA fibrous mats resulted in a dosedependent expansion of mesenchymal progenitor-like cell layers and ECM
deposition.
FGF9-loaded PEA fibrous mats were implanted onto the TA muscle of B6 mice (n = 3),
for 7 days to evaluate the effect of FGF9 controlled delivery (0, 120, 240, 480 ng/cm 2)
from the PEA fibers on cell niche recruitment (A-D), respectively. Blue arrows are pointing
to the PEA fibrous mats with insets of higher magnification for the skin and muscle sides,
red arrows point to the encapsulated inflammatory cells, and green bracket indicate the
organized mesenchymal progenitor-like cell layers. Scale bar = 100 µm.
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Discussion
The differential delivery of more than one growth factor from a single electrospun
biomaterial has not been achieved as yet. The strategy developed in previous studies is to
use a polymer blend, or multiple polymers each of which is loaded with one growth factor,
and electrospun to form composite delivery systems [8, 38-40]. As an example,
nanocomposite bone scaffolds, where FGF18-preloaded mesoporous bioactive glass
nanospheres were incorporated within the FGF2-loaded core–shell electrospun
polycaprolactone and poly(ethyleneoxide) fibers for bone regeneration were reported [39].
In another study, collagen-gelatin-hyaluronic acid composite delivery system
incorporating three growth factors for wound healing was also reported [38]. In our study,
a single α-amino acid-derived biomaterial that degrades by surface erosion [32, 41], was
utilized for dual loading and differential release of FGF2 and FGF9 for therapeutic
angiogenesis application. The in vitro release data showed sustained and differential
delivery of FGF2 and FGF9 from the PEA electrospun fibers (Figure 4-1 C), which can
positively influence the natural angiogenesis process; where the angiogenic growth factor
(FGF2) plays an early role in the nascent tube formation stage, while the arteriogenic
growth factor (FGF9) is needed later on in the process of vessel maturation and
stabilization [42-44]. FGF2 was previously loaded into electrospun fibers using blend,
emulsion and coaxial electrospinning [45-47], or through heparin immobilization onto
polycaprolactone electrospun scaffolds [48]. However, the complexity of the angiogenesis
process and the need for more than one growth factor for functional vascular tissue
formation suggest the use of a differential and sustained delivery approach in order to
pattern neovascular maturation.
Angiogenesis is a multifaceted process that starts with the migration and proliferation of
endothelial cells in response to angiogenic factors, followed by their remodeling into tubes.
Subsequently, the maturation of the newly formed vessels requires the recruitment of
mural cells [49]. The in vitro angiogenesis assays data demonstrated that HCAECs treated
with the co-released FGF2 and FGF9 from the FGF2/FGF9-dual loaded PEA fibers showed
enhanced tube formation (Figure 4-2). Moreover, HCASMCs treated with FGF2/FGF9dual loaded fibers exhibited enhanced migration to PDGF-BB (Figure 4-3 A-B), which was
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expected due to FGF2–induced increase in surface expression of α2β1 integrin [34] and
FGF9-induced upregulation of platelet derived-growth factor receptor β (PDGFRβ) in
human vascular SMCs, reported in previous work [22, 32, 50]. Furthermore, previously
the upregulation of PDGFRβ have been shown to be mediated by sonic hedgehogPDGFRβ-dependent signaling [22]. Although the angiogenic synergism between FGF2
and PDGF-BB has been reported [51], upregulating the receptor (PDGFRβ) via FGF9 is a
more valid approach than delivering the PDGFRβ ligand. PDGF-BB delivery has been
implicated to abolish the natural gradients of PDGF-BB required for SMC recruitment [52],
whereas FGF9 delivery would not. Also, in the case of treating HCASMC/HCAEC coculture with the co-released FGF2 and FGF9, enhanced SMC-EC interaction was observed
further stabilizing in vitro tube formation (Figure 4-4). In view of all this, dual delivery of
FGF2 and FGF9 additively enhanced directed SMC migration and vessel stability.
Biomaterials are implanted into a host either as delivery vehicles for delivering drugs and
growth factors or as a tissue replacement. In either case, inflammatory response is
inevitable. Although inflammation is associated with negative outcomes (e.g. fibrosis and
implant rejection), some inflammatory reactions can promote biomaterial-tissue
integration [53-55]. This is particularly beneficial if the implant is a tissue-engineered
construct since the presence of macrophages could potentially yield a positive influence on
stem cell recruitment and differentiation, allowing tissue integration, regeneration, and
healing. Emerging data [53, 56] demonstrated that the positive influence of macrophages
to be the result of a transition from a pro-inflammatory (M1) phenotype to a regulatory or
anti-inflammatory M2 phenotype, thus promoting functional outcomes instead of scar
tissue formation [56]. Scaffold surface topography appeared to be partially responsible for
this phenotype transition since it affects monocyte/macrophage activation [57]. In addition
to topography effects, implant integration to the host is facilitated by monocyte
chemoattractant protein-1 (MCP-1). For instance, when vascular scaffolds fabricated from
polyglycolic acid were seeded with bone marrow mononuclear cells (BMC) and implanted
in mice, MCP-1 was secreted by BMC enhancing monocyte recruitment, which in turn
recruited vascular progenitor cells [58]. Notwithstanding the above, inflammatory reaction
to scaffolds loaded with growth factors/drugs is not generally desirable [24, 26, 59]. The
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reason for this requirement is that inflammatory reaction often accelerates degradation of
the scaffold implying rapid release of the payload instead of sustained release. Conversely,
inflammatory reaction could also form a layer of fibrous capsule on the scaffold, which
could potentially delay the release of the loaded growth factors. Induced inflammation and
host response often preclude many synthetic biomaterials from growth factor-delivery
applications [60]. This new class of α-amino acid-derived biodegradable PEAs, which are
susceptible to either hydrolytic or enzymatic degradation [30, 61, 62], showed minimal
induced inflammatory response in vitro (Figure 4-5). Moreover, subcutaneous implantation
of the unloaded and the FGF2/FGF9-dual loaded PEA fibers in B6 mice did not induce
significant inflammatory cell infiltration or scar formation (Figure 4-6). This was attributed
to the naturally occurring degradation by-products that can be metabolized physiologically,
limiting their potential inflammatory response and systemic toxicity [29]. Moreover, the
degradation mechanism is governed by surface erosion [32], which limits the localized
accumulation of acidic degradation by-products, thus avoiding significant pH decrease in
the vicinity of the fibrous mat that usually results in inflammatory responses [63].
In this study robust cell niche recruitment was observed around the FGF2/FGF9-loaded
PEA fibers when implanted subcutaneously in mice. Cell niche recruitment is most likely
attributed to FGF9 [22], and the H&E sections of the FGF9-loaded PEA fibers implanted
onto the tibialis anterior muscle of B6 mice for 7 days confirmed that controlled delivery
of FGF9 resulted in a dose-dependent recruitment of mesenchymal progenitor-like cells
that were organized in layers and deposited extracellular matrix (Figure 4-7 A-D). FGF9
has been reported to amplify mesenchymal progenitors in developing tissues [20, 64], and
to maintain SMC progenitor cells in embryonic microvascular development [65]. FGF9 is
expected to stimulate vascular maturation via recruitment of SMC progenitors to the
nascent endothelial tubes and differentiation of some of this cell niche into contractile
SMCs [22]. This highlights the role of the mesenchyme-targeting growth factor (FGF9)
and its controlled delivery in the process of vascular maturation. In future studies, ischemic
hindlimb mouse model will be utilized to examine the potential of FGF2/FGF9 dual-loaded
PEA fibers to regenerate competent vasculature and to identify the recruited cell niche.
Taken together, this data suggests the versatility of electrospun α-amino acid-derived PEA
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fibers as promising candidates for the controlled delivery of angiogenic and arteriogenic
growth factors with relevance to therapeutic angiogenesis and vascularization of in vitro
tissue-engineered constructs.

Conclusions
Differential presentation of angiogenic and arteriogenic growth factors is beneficial to
induce stable neovascularization. In this study, it has been shown that FGF2/FGF9 dualloaded PEA fibers can be potential candidates for sustained and localized co-delivery of
growth factors. The differentially released FGFs enhanced the directed SMC migration to
PDGF-BB and stabilized tube formation in vitro. Particularly controlled delivery of FGF9
in vivo resulted in a dose-dependent recruitment of mesenchymal progenitor-like cells that
were organized in layers and deposited ECM. Altogether, with the absence of any induced
inflammatory response in vitro or in vivo, FGF2/FGF9 dual-loaded PEA fibers can have a
promising therapeutic angiogenesis application for treatment of ischemic vascular diseases.
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Chapter 5
5
In vivo Evaluation of FGF-loaded Electrospun Poly(ester amide)
Fibers for Therapeutic Angiogenesis
Overview: This chapter focuses on the in vivo angiogenesis evaluation of the FGF-loaded
PEA fibers using the ex ovo chick choriallantoic membrane model coupled with power
Doppler ultrasound imaging and the ischemic hindlimb mouse model followed by CatWalk
assay and histological analysis.

Abstract
Angiogenic protein therapies have shown great promise in preclinical studies; however,
limited positive results have been achieved from clinical angiogenesis trials, in part, due to
neovessel regression. A major limitation of angiogenic protein therapy is the rapid
degradation and clearance from the site of delivery due to the short half-life of these
exogenous angiogenic factors, resulting in a temporary therapeutic effect at the tissue of
interest. Controlled delivery of angiogenic growth factors from polymeric-delivery system
could overcome the aforementioned challenge. In this study, electrospun poly(ester amide)
(PEA) fibers have been loaded with either fibroblast growth factor-9 (FGF9) alone or with
FGF9 and fibroblast growth factor-2 (FGF2) to maintain a controlled release of these
growth factors in a bioactive form over a period of months in an attempt to achieve vessel
maturation and stabilization. FGF-loaded PEA fibers were evaluated using two in vivo
models, the chick chorioallantoic membrane (CAM) model as a screening platform and the
ischemic hindlimb mouse model as a pathological pre-clinical model. The CAM assay
coupled with 3D power Doppler vascular quantification showed localized angiogenic
effects at regions beneath the FGF-loaded fibrous mats. Moreover, the implantation of the
FGF9-loaded PEA fibrous mats on the surface of infarcted tibialis anterior muscle resulted



A version of this chapter is currently in preparation to be submitted for publication as “Somiraa S. Said,
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in an enhanced skeletal muscle regeneration and increased abundance of mural-wrapped
microvessels compared with the unloaded fibers control group as demonstrated by
histological analysis. This supports the hypothesis that controlled delivery of FGF9 from
electrospun PEA fibers enhances the assembly of functional and stable microvessels.

Key words: Angiogenic protein therapy; Poly(ester amide) electrospun fibers; Fibroblast
growth factor-2; Fibroblast growth factor-9; CAM angiogenesis assay; Ischemic hindlimb
mouse model.

Introduction
In vitro angiogenesis assays are quantitative and efficient but their findings should be
confirmed by in vivo models. In vivo assays are more laborious and challenging to
quantitate; however, the formation of functional blood vessels involves complex
interactions between multiple cell types, which necessitates preclinical testing. Simple
animal models such as the chick chorioallantoic membrane (CAM) [1, 2], zebra fish
embryo [3, 4] and rabbit corneal pocket [5] have been widely used to assess angiogenesis
in vivo. Clinically-relevant animal models have also been used to demonstrate the potential
of angiogenic therapies for myocardial and peripheral ischemia [6]. Myocardial ischemia
is most commonly induced by ligation of the anterior descending branch of the left
coronary artery [7] or by placing ameroid constrictors around the coronary artery [8].
Hindlimb ischemia is typically induced by ligation and/or excision of the common femoral
artery or iliac artery [9, 10], with or without accompanying ligation of collateral vessels.
In animal models, histological demonstration of enhanced angiogenesis and tissue healing
or perfusion after an acute arterial occlusion is a common preclinical endpoint [6];
however, the functionality of the newly formed vessels and the restoration of the ischemic
muscle function should also be considered in animal models. The most studied growth
factors in animal models for therapeutic angiogenesis are vascular endothelial growth
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factor (VEGF), fibroblast growth factor-2 (FGF2) and platelet-derived growth factor
(PDGF)-BB [6].
In this chapter, the chick CAM model is proposed as an in vivo angiogenesis assay to
evaluate the developed FGF2/FGF9 dual loaded PEA fibrous mats. Since the chick embryo
is a living system, this model provides a simplistic physiological system for in vivo analysis
than the in vitro assays. The CAM is the extraembryonic membrane that lies directly under
the egg shell of all avian species allowing for gas and nutrient exchange [11, 12]. It is
highly vascular, readily accessible, relatively immunotolerant and inexpensive [13]. Large
numbers of eggs can be prepared for the CAM assay in a relatively short time and the
results can be quantified rapidly with minimal equipment allowing for large-scale
screening. This system has been used for the study of vascular development and
angiogenesis [14]. Because of its rapid vascular growth, many pro- and anti-angiogenic
agents have been tested by quantifying the morphological responses of the CAM
vasculature [15]. Moreover, it is possible to test controlled release delivery systems via
local application on the CAM surface [1], and the lack of excretion allows to preserve the
concentration of bioactive reagents in the circulation for extended period of time [13].
Power Doppler ultrasound imaging of the CAM allows for better interpretation of vascular
remodeling in the local microenvironment of the angiogenic therapy.
Since a single in vivo model is usually inadequate to fully investigate the process of
angiogenesis, a more clinically relevant model, the ischemic hindlimb mouse model, was
considered to further investigate the potential of FGF9-loaded electrospun PEA fibers to
induce the formation of mature vasculature in ischemic conditions. Ischemic conditions
usually creates high FGF2 gradient in the affected tissue [16], which minimizes the need
for FGF2 controlled delivery. If a sufficient amount of FGF9 is delivered to the ischemic
tissue, it may act in the local microenvironment where most of the growth factors, their
receptors and signaling pathways necessary for the vascular remodeling are already present
[17-19]; therefore, it will not need to initiate and maintain the whole complicated process
of angiogenesis. Hence, the study focused on the local and controlled delivery of FGF9
and testing the effects of FGF9-loaded PEA fibrous mats on tissue regeneration and new
microvessel stabilization using the ischemic hindlimb mouse model.
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In the current study, FGF-loaded PEA fibrous mats were studied using two in vivo models;
the CAM model coupled with power Doppler ultrasound imaging to study localized
angiogenesis, and the ischemic hindlimb model followed by quantitative CatWalk gait
assay and histological analysis including H&E and double immunofluorescent staining to
study tissue regeneration and mature neovessel formation.

Material and Methods
5.3.1

Materials

The poly(ester amide) 8-Phe-4 was synthesized from L-phenylalanine, sebacoyl chloride,
and 1,4-butanediol through interfacial polymerization and characterized as described in
previous publications [20, 21]. Recombinant human FGF9 and FGF2 were purchased from
R&D Systems, Inc. (Minneapolis, MN). Hank’s balanced salt solution was purchased from
Invitrogen Canada (Burlington, ON). The FGF-loaded PEA fibers were fabricated by the
electrospinning technique and characterized as previously reported [21, 22].

5.3.2
Chick Chorioallantoic Membrane (CAM) as an Angiogenesis Screening
Platform for FGF2/FGF9 Dual-loaded PEA Fibrous Mats
Fertilized White Leghorn chicken eggs were obtained from McKinley Hatchery (St
Mary’s, ON, Canada). Eggs were incubated for three days at 38 °C and 80% relative
humidity (RH) in a rotating hatcher (Sportsman hatcher, Berry Hill, ON). On Day 4 postfertilization, the eggs were removed from the hatcher and were cracked gently using a
blade. The embryos were transferred into weighing boats with a plastic cover, an ex ovo
culture system, to expose the CAM and make it accessible for imaging (Figure 5-1). The
ex ovo culture protocol is previously described [23]. The shell-less chick embryos were
returned to the incubator (38 °C, ~80% RH) till Day 10.
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Figure 5-1: The ex ovo CAM cultivation protocol steps.
(a) Gentle cracking of the egg using a blade, (b) transferring the contents into weighing
boats and (c) covering with a plastic cover. Adapted from [15].

5.3.2.1

Experimental Design

On Day 10, the CAMs were retrieved from the incubator to start the study. Four test
conditions were examined to study the vascular density increase of the full CAM surface:
soluble growth factors on KimwipeTM (1 cm × 1 cm) (10 µL FGF2 solution and 10 µL
FGF9 solution in PBS at a concentration of 1 ng/µL), unloaded PEA fibers (1 cm × 1 cm),
FGF2/FGF9 dual-loaded PEA fibers (1 cm × 1 cm), and control (no fibers). The samples
were conditioned overnight in Hank's balanced salt solution (HBSS) before placing on the
CAM. To maintain the temperature during the experiment, the chick embryos were placed
over a warming pad (Gaymar Industries, Inc., Orchard Park, NY) set to 40 °C. A total of 3
CAMs were used for each condition and the experiment was repeated three times. The
CAMs were supplemented with 50 µL of HBSS at pre-determined time intervals to keep
the mats moist, which could assist in the process of growth factor diffusion. Each CAM
was digitally photographed at Day 0, 2, 5, and 8, and then imaged using power Doppler
ultrasound at Day 8 when the vascular network of the CAM fully matures as previously
reported [12]. The embryos were allowed to stabilize for 2-5 minutes prior to image
acquisition. All procedures complied with the guidelines of the Canadian Council on
Animal Care.
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5.3.2.2

Image Acquisition

Digital photographs (2448 × 2448 pixels) of the full CAM surface were captured using a
Samsung Galaxy S6 camera (16 MP, Samsung Electronics Canada Inc., Mississauga, ON).
The phone was placed on a custom made stage designed to keep the phone parallel to and
at a fixed height from the CAM surface. Three dimensional (3D) power Doppler images of
the CAM vasculature were acquired using a 40 MHz linear array transducer (MS550D,
FUJIFILM VisualSonics, Inc., Toronto, Canada) and Vevo 2100 high-frequency imaging
system (FUJIFILM VisualSonics, Inc) setup to the digital RF mode. The settings were
fixed throughout the study (frequency, 40 MHz; power, 100%; B-mode gain, 22 dB; power
Doppler gain, 12 dB; dynamic range, 65 dB; pulse repetition frequency, 1 kHz; wall-filter,
low). Warmed Aquasonic 100 ultrasound transducer gel (Parker Laboratories, Inc., NJ,
USA) was applied to the transducer face and used for coupling between the transducer and
the CAM surface. Few drops of warmed saline were applied to the CAM surface at the
CAM-transducer contact area as a lubricant to prevent sticking of the CAM surface to the
transducer gel. Imaged regions of interest (ROI) were set to (lateral × axial × elevation =
13.88 × 10.00 × 14.10 mm with an elevation spacing between B-mode planes of 0.0762
mm) and were selected to include clear arterial and venular branching patterns far enough
from the embryo body to reduce reflection and motion artifacts. The 3D power Doppler
images were exported in the quadrature demodulated (IQ).

5.3.2.3

Digital Image Pre-processing

Using the full view of the CAM surface, the scale was calibrated using the reference
dimensions of the plastic weighing boats carrying the embryos (89 mm × 89 mm). Images
were then cropped keeping only the region showing the vascular network of the CAM using
the polygon selection tool in Fiji software (NIH, Maryland, USA) [24]. The percentage
vascular density, the number of pixels representing vessels (white pixels) divided by the
total number of pixels in the ROI × 100, was automatically calculated from the cropped
images using Vessel Analysis plugin for Fiji software developed by Nivetha Govindaraju
and Mai Elfarnawany [URL link to the page: http://imagej.net/Vessel_Analysis]. The
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plugin applies a series of filters, noise reduction, thresholding and binarization functions
to the ROIs prior to estimating the vascular density. The pre-processing steps and a sample
of the final binary image are shown in Figure 5-2.

Figure 5-2: Steps of digital image pre-processing to produce the final binary CAM
image used in percentage vascular density analysis.

5.3.2.4

Power Doppler Processing and Vascular Quantification

Power Doppler quadrature demodulated (IQ) data was processed using software
implemented in MATLAB R2013a (The MathWorks, Inc., MA, USA) to apply the twostage method for power Doppler microvascular angiography developed by Elfarnawany et
al. [25, 26]. In the first stage, the wall filter cut-off frequency is spatially tuned for local
variations in the processed image using the wall filter selection curve (WFSC) method [27].
The 3D power Doppler volume of the vascular network is reconstructed from the spatially
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tuned images. In the second stage, a 3D vessel tree is extracted from the power Doppler
volume by applying a 3D skeleonization algorithm followed by reconstruction of the full
diameters of the vessels along the skeletons. To retain the intensity values of the power
Doppler signal in the final image, the original 3D power Doppler volume is masked using
the 3D vessel tree resulting in a power-weighted 3D vessel tree with reduced color voxel
artifacts.

The resulting 3D power Doppler vessel tree was quantified using the three standard power
Doppler angiography metrics [28]:
𝑉𝑎𝑠𝑐𝑢𝑙𝑎𝑟𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑖𝑛𝑑𝑒𝑥 (𝑉𝐼) =

𝐹𝑙𝑜𝑤 𝑖𝑛𝑑𝑒𝑥 (𝐹𝐼) =

𝑐𝑜𝑙𝑜𝑟 𝑣𝑜𝑥𝑒𝑙𝑠
𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑥𝑒𝑙𝑠 𝑖𝑛 𝑅𝑂𝐼

𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑐𝑜𝑙𝑜𝑟 𝑣𝑜𝑥𝑒𝑙𝑠
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑜𝑙𝑜𝑟𝑒𝑑 𝑣𝑜𝑥𝑒𝑙𝑠 (𝑚𝑚3 )

𝑉𝑎𝑠𝑐𝑢𝑙𝑎𝑟𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑓𝑙𝑜𝑤 𝑖𝑛𝑑𝑒𝑥 (𝑉𝐹𝐼) =

𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑐𝑜𝑙𝑜𝑟 𝑣𝑜𝑥𝑒𝑙𝑠
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑥𝑒𝑙𝑠 𝑖𝑛 𝑅𝑂𝐼 (𝑚𝑚3 )

where, VI measures the proportion of color voxels in the ROI, representing the amount of
moving blood in the tissue, FI, the mean power signal of blood flow, represents the
intensity of flow at the time of acquisition and VFI is a combination of vascularization and
flow indices representing both blood flow and vascularization. The denominators of the FI
and VFI metrics were modified by Elfarnawany et al. [26] from their original definition
by replacing the number of voxels by the total volume occupied by these voxels in mm3 to
compensate for longitudinal variations in the voxel size when using differently sized
Doppler ROIs at different time points. These three vascularization measurements were
calculated from the 3D power Doppler volumes for the four test conditions and compared
to give an idea about the quality of the induced vasculature in the localized volume of the
CAM underneath the fibrous mats.

117

5.3.3
Ischemic Hindlimb Mouse Model: In vivo Angiogenesis Assay for FGF9loaded PEA Fibers
5.3.3.1

Experimental Design

Male C57BL6/J mice 3 month of age were anesthetized by Isoflurane inhalation (Forane®,
Baxter, Deerfield, IL) and hindlimb ischemia was induced as described in Figure 5-3 [9].
Briefly, the right femoral artery was exposed through an incision in the skin overlying the
middle portion of the hind limb. The femoral artery was ligated above and below the
profunda femoris branch using 6-0 silk sutures. The artery and vein with all side-branches
were dissected, avoiding the femoral nerve, and the intervening 5–6 mm portion of artery
was excised. Nine mice were used per group (FGF9-loaded vs unloaded fibers group).
FGF9-loaded fibrous mats (~2 ng release per cm2 per day) and control of unloaded fibrous
mats were implanted subcutaneously on the calf region, as a layer of 5 mm × 7 mm sheet,
at the interface between the skin and tibialis anterior (TA) muscle. The fibrous mat covered
the lower 2/3 of the TA muscle surface. The fibers were pre-implanted 3 days before
hindlimb ischemia was induced. Seven days post-ischemia induction, mice were subjected
to CatWalk gait analysis and then sacrificed and the calf tissues were harvested for
histological analysis. All animal procedures were approved by the Council on Animal Care
of the University of Western Ontario and were in accordance with the guidelines of the
Canadian Council on Animal Care.
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Figure 5-3: Surgical procedure for induction of hindlimb ischemia by femoral
artery ligation in C57BL6/J male mice.
Ventral aspect of right mouse thigh and upper hind limb after hair removal (a). Surgical
skin incision (5 mm) beginning from the groin skinfold following and immediately lateral
to the vascular contours visible through the skin (b). Blunt dissection and separation of the
femoral artery and vein (c). Insertion of surgical thread underneath the femoral artery (d).
Faint appearance of collaterals from the deep branch (arrowhead). Ligation of the femoral
artery distal to the origin of the deep branch by a triple surgical knot (e). Blood flow is
diverted to collaterals (dashed white arrow) and collateral arteries now appear prominent
(compare arrowheads from d and e). Over-and-over skin suture (f). Scale bars = 2 mm.
Used with permission from Macmillan Publishers Limited [9] © 2009.
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5.3.3.2

CatWalk Automated Quantitative Gait Analysis

CatWalk assay is a highly sensitive tool to assess gait and locomotion. The mouse traverses
a glass plate voluntarily, and its footprints are captured. It visualizes the prints and
calculates statistics related to print dimensions and the time and distance relationships
between paw falls. CatWalk assay usually used in neurological research, but it has been
used in this study to assess functional recovery of the ischemic hindlimb by determining
the extent to which the injured limb was used for walking [29]. The mice were subjected
to the CatWalk assay at Day 7, and the average of at least 3 runs across the glass plate of
an enclosed walkway was used for further analysis by the Noldus 7.1 software (Noldus
Information Technology Inc., Leesburg, VA). In the CatWalk system, LED light from a
fluorescent lamp illuminates the inside of the glass floor plate of the walkway. Light is
reflected downward at sites of paw contact with the upper surface of the glass plate, the
intensity of which is proportional to the relative force being exerted by the paw. Light
reflection was recorded with a video camera and analyzed to determine the print intensity,
print area and duty cycle for comparison between the FGF9-loaded fibers and the unloaded
fibers-treated mice groups. Print intensity is expressed as the mean brightness of all pixels
of the print at maximum contact, the print area (mm2) is the surface area (in pixels) of the
complete print, while the duty cycle (%) expresses the stance duration as a percentage of
the duration step cycle including stands and swings. All values were normalized to the
contralateral healthy (left) hindlimb and expressed as mean percentage.

5.3.3.3

Histological Analysis

The mice were sacrificed at Day 7 and perfusion-fixed with 4% paraformaldehyde (PFA).
The whole hindlimbs were immersed in 4% PFA overnight. The anterior calf muscle
bundle was isolated and fixed with 4% PFA for another 24 h before paraffin embedding.
Muscle tissues, including TA, extensor digitorum longus (EDL) and palmaris longus (PL)
muscles, were cross-sectioned at 5 μm thickness and subjected to hematoxylin and eosin
(H&E) staining, or double-immunostained using biotinylated rat anti-mouse CD31
antibody (Clone MEC13.3, BD Biosciences) and mouse anti-smooth muscle α-actin (SM
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α-actin) antibody conjugated with alkaline phosphatase (Clone 1A4, Sigma), or rat antimouse endomucin antibody (V.7C7, Santa Cruz) and rabbit anti-NG2 Chondroitin sulfate
proteoglycan antibody (AB5320, EMD Millipore). Images were acquired on an Olympus
IX51 inverted microscope equipped with North Eclipse software, using 20× and 40×
objective. Due to inter-individual variation in muscle regeneration at Day 7, the
histological comparison was limited to regions with similar degree of myofiber
regeneration in the TA muscle. Five ROIs per section were analyzed qualitatively for H&E
stained sections in terms of induced inflammation and the degree of regeneration of the
infarcted TA muscle, and quantitatively for double-immunofluorescent stained sections by
counting mural-covered microvessels (SM α-actin or NG2 positive microvessels) using
ImageJ software.

5.3.4

Statistical Analysis

Data is presented as mean ± SEM for experiments conducted in triplicate. Statistical
analysis was conducted with t-test or one-way ANOVA followed by Tukey’s multiple
comparison test using GraphPad Prism 4 software (GraphPad Software, Inc., CA, USA).
Probability values less than 0.05 were considered statistically significant, unless otherwise
was specified.

Results and Discussion
5.4.1
FGF2/FGF9 Dual-loaded PEA Fibers Induced Localized Angiogenesis in
CAM Model

5.4.1.1

Analysis of Vascular Density of the Full CAM Surface

Figure 5-4 A shows the digital photographs (2448 × 2448 pixels) of the full CAM surface,
captured using a Samsung Galaxy S6 camera and the images were processed using ImageJ
software, following the previously described scheme (Figure 5-2). The percentage increase
in vascular density of the CAM at each time-point was calculated by subtracting the initial
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vascular density at Day 0 for each chick embryo from the vascular density at Day 2, 5, and
8. The digital images showed a qualitative increase in vascular density of the CAMs treated
with the 4 test conditions with time; however, there was no significant difference in the
vascular density of the CAM between the 4 test conditions at Day 2, 5, and 8 (Figure 5-4
B). The ex ovo CAM model had some limitations in detecting a significant increase in
vascular density of the full CAM vasculature due to its rapid vascular growth that outpaced
the controlled and relatively slow release of FGF2 and FGF9 from the PEA fibers.
Furthermore, the released amount of growth factors from the fibers might not have reached
the effective therapeutic dose to induce significant angiogenesis in the full CAM surface.

Figure 5-4: The effect of FGF2/FGF9 dual-loaded PEA fibers on CAM vasculature.
(A) Digital photographs of the full CAM surface, (B) Percentage increase in vascular
density of the full CAM vascular density calculated at pre-determined time intervals (Day
2, 5, and 8) for the control (no fibers), CAMs treated with soluble growth factor, unloaded
PEA fibers, and FGF2/FGF9 dual-loaded PEA fibers with respect to Day 0. Scale bar = 10
mm, (n=3).
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5.4.1.2

Vascular Quantification Using 3D Power Doppler Volumes of the CAM

The 2D power Doppler images showed an increase in the CAM thickness in case of the
soluble GFs on KimwipeTM group with the soluble growth factors, unloaded PEA fibers,
and the FGF2/FGF9 dual-loaded PEA fibers compared to the control (no fibers), which
might be due to induced inflammation of the CAM surface, as indicated by the increased
thickness of the CAM tissue (Figure 5-5). Nevertheless, it is worth noting that the induced
inflammation due to the PEA fibers was much less than that induced in the soluble GFs on
KimwipeTM group (Kimwipe was used in the study to confine the GF solution and provide
comparable conditions to the PEA fibrous mat). Furthermore, the PEA fibers were more
flexible and adapting with the increased vascularity of the CAM surface with time.

Figure 5-5: The power Doppler 2D images of the control (no fibers), CAMs treated
with soluble growth factor, unloaded PEA fibers, and FGF2/FGF9 dual-loaded PEA
fibers, acquired at Day 8.
The power Doppler 2D images show transverse sections of the CAM tissue represented
in gray scale and the vessels represented in red.
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Moreover, the fibers did not interrupt the vascular network of the CAM underneath, which
resulted in slight bending of the horizontal vessel network when compared to the control
as shown in the power Doppler 3D volumes (Figure 5-6). In addition, the 3D volumes
showed the formation of smaller vessels near the CAM surface in case of the dual-loaded
PEA fibers and soluble GFs on KimwipeTM treated CAMs, which were not observed in
case of the unloaded PEA fibers treated and the control CAMs (Figure 5-6). This suggests
a localized angiogenic effect at the interface between the fibrous mat and the CAM surface.

Figure 5-6: The power Doppler 3D vessel trees resulting from applying the two-stage
signal processing method for power Doppler angiorgraphy [26].
3D volumes for ROIs (lateral × axial × elevation= 13.88 × 10.00 × 14.10 mm with elevation
spacing between B-mode planes of 0.0762 mm) of the control, and CAMs treated with
soluble growth factor, unloaded PEA fibers, and FGF2/FGF9 dual-loaded PEA fibers,
acquired at Day 8.
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Furthermore, vascular quantification of the 3D power Doppler volumes was carried out
using modified Pairleitner et al. equations [28]. Vascularization and flow metrics for VI,
VFI, and FI (Figure 5-7) indicated a statistically significant increase in vascularization and
vascularization flow indices (VI and VFI) for the dual-loaded PEA fibers group versus the
unloaded PEA fibers group, which might indicate the assembly of a better quality
microvessels and increased amount of moving blood in the CAM underneath the fibrous
mat owing to the controlled release of FGF2 and FGF9.

Figure 5-7: Vascular quantification of the power Doppler 3D volumes of the control,
and CAMs treated with soluble growth factor, unloaded PEA fibers, and FGF2/FGF9
dual-loaded PEA fibers, acquired at Day 8 (n=3), (* p < 0.05, *** p < 0.0001).
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5.4.2
Controlled Release of FGF9 from PEA Fibers Stimulated Stable
Microvessel Formation in Ischemic Hindlimb Mouse model
In order to assess whether the controlled release of FGF9 from PEA fibers promotes
neovessel formation and maturation in ischemic conditions, FGF9-loaded PEA fibrous
mats were implanted directly onto the TA muscle of B6 mice subjected to femoral artery
ligation 3 days post-implantation.

5.4.2.1
Functional Recovery of the Ischemic Hindlimb upon Implantation of
FGF9-loaded PEA Fibrous Mats
Functional recovery of the ischemic hindlimb by the controlled delivery of FGF9 was
assessed using CatWalk analysis of mice traversing an illuminated glass plate and its foot
prints were recorded. At Day 7 post-ischemia, there was no statistically significant
difference (p > 0.05) between the print intensity, print area and duty cycle of the injured
hindlimbs treated with FGF9-loaded fibers compared with those treated with unloaded
PEA fibers in terms of usage of the injured limb for weight bearing (Figure 5-8). Detection
of significant differences in terms of functional recovery of the injured limbs at Day 7 postischemia might be too early, so longer time-point studies (28 days) are proposed in order
to evaluate the effect of controlled delivery of FGF9 on reversing ischemia and restoration
of function.
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Figure 5-8: CatWalk automated quantitative gait analysis for mice treated with
unloaded and FGF9-loaded PEA fibrous mats.
The values for (A) the print intensity, (B) print area and (C) duty cycle for the ischemic
limb at Day 7, were normalized to that of the contralateral healthy limb and expressed as
mean%, (n = 9) and each dot represents one mouse.

5.4.2.2
Histological Analysis of the TA Muscle Using H&E and Doubleimmunofluorescent Staining
Histological analysis of tissues harvested 7 days post-ischemia showed enhanced
regeneration of the infarcted TA muscle and increased angiogenesis with reduced
inflammation and minimal tissue necrosis as illustrated by the H&E photomicrographs
(Figure 5-9). Moreover, a reduced presence of interstitial adipocytes in the regenerating
skeletal muscle zone was observed for the injured hindlimbs treated with FGF9-loaded
fibers.
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Figure 5-9: H&E staining of the histological sections of the TA muscle.
Photomicrographs of the TA muscle (20× objective) harvested at Day 7, (A) without
infarction and after implantation of (B) unloaded PEA fibers and (C) FGF9-loaded PEA
fibers 3 days prior to infarction (scale bar = 100 µm).

Fluorescence microscopy images of the TA muscle double-immunolabeled for CD31 and
SM α-actin showed no difference in the number of CD31-positive microvessels between
the TA muscles treated with unloaded and FGF9-loaded fibers (Figure 5-10). However,
controlled delivery of FGF9 resulted in a statistically significant increase (p < 0.05) in the
proportion of microvessels invested by SM α-actin–containing mural cells (Figure 5-10
B&D).

NG2 is a pericyte cell marker; it is expressed in nascent microvessels by vascular pericytes
[30]. While, endomucin is a sialomucin or CD164 that is specifically expressed on the
endothelium of adult mice during development of the vascular system [31]. Using NG2 as
mural cell marker could give us further insights into the recruitment of mural cells by FGF9
and their investment of the neomicrovessels. Results from the NG2/endomucin double
immunostaining of the TA muscle were similar to that observed from the CD31/SM αactin double immunostaining, showing a statistically significant increase (p < 0.01) in the
proportion of microvessels invested by NG2–containing mural cells, which confirms the
enhanced mural cell wrapping of the microvessels due to the controlled release of the FGF9
(Figure 5-11).
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Figure 5-10: CD31/SM α-actin double immunostaining of histological sections of the
TA muscle at Day 7 and quantitative estimation of SM α-actin+ microvessels at the
skin side.
Fluorescence microscope images of TA muscle (40× objective) harvested 7 days after
implantation of (A) unloaded PEA fibers and (B) FGF9-loaded PEA fibers, double
immunolabeled for CD31 (red) and SM α-actin (green). Quantitative estimation of (C) the
number of CD31+ arteriole-like microvessels at the skin side per high power field (40×
objective), and (D) percentage of SM α-actin+ microvessels normalized to the total number
of CD31+ microvessels per field (n = 9). Scale bar = 50 µm and arrows are pointing to
CD31/SM α-actin+ microvessels (* p < 0.05).
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Figure 5-11: Endomucin/NG2 double immunostaining of histological sections of the
TA muscle at Day 7 and quantitative estimation of NG2+ microvessels at the skin side.
Fluorescence microscope images of TA muscle (40× objective) harvested 7 days after
implantation of (A) unloaded PEA fibers and (B) FGF9-loaded PEA fibers, double
immunolabeled for endomucin (green) and NG2 (red). Quantitative estimation of (C) the
number of endomucin+ arteriole-like microvessels at the skin side per high power field
(40× objective), and (D) percentage of NG2+ microvessels normalized to the total number
of endomucin+ microvessels per field (n = 9). Scale bar = 50 µm and arrows are pointing
to endomucin/NG2+ microvessels (** p < 0.01).
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Polymer-based delivery vehicles offer great potential to deliver biologically active growth
factors in a controlled fashion over a period of days to months to promote
neovascularization [32-35]. Mooney and colleagues studied the use of injectable alginate
hydrogel with PLGA microspheres for sequential delivery of VEGF and PDGF-BB in a
myocardial infarction mouse model [36]. Cao et al. investigated the co-delivery of VEGF
and PDGF-BB or the co-delivery of FGF2 and PDGF-BB, adsorbed onto heparinized
sepharose beads embedded into Matrigel, to ischemic hindlimb model of rat and rabbit
[37]. Formation of stable vasculature was observed for the co-delivery of FGF2 and PDGF,
while vessel size and maturity was enhanced by sequentially delivering VEGF and PDGF
[36-38]. However, VEGF can inhibit vessel maturation during PDGF-mediated
angiogenesis [39]. Previous studies has shown that co-delivery of FGF2 and fibroblast
growth factor-9 (FGF9) by the means of an osmotic pump to mouse ischemic hindlimb
resulted in mature, persistent, and vasoreactive microvessels [40].
As described in Chapter 4, FGF2 and FGF9 were dual-loaded into biodegradable
electrospun poly(ester amide) (PEA) fibers, which showed enhanced endothelial tube
formation, increased smooth muscle cell migration and improved endothelial cell-smooth
muscle cell interaction in vitro [22]. Building up on the previous promising results, it was
desired to investigate its efficacy in induction of mature neovessel formation using in vivo
models. FGF9 is a mesenchyme-targeting growth factor that plays a crucial role in the
recruitment of mural cells and the formation of physiologically mature and stable
neovessels [40]. It acts mainly through sonic hedgehog signaling, an upstream regulator of
PDGFRβ expression [40], and the PDGF-BB/PDGFRβ signaling pathway was reported to
be pivotal to recruiting SMCs and pericytes to the developing vasculature [41]. Controlled
delivery of FGF9 from PEA fibers will protect FGF9 from rapid degradation and clearance
from the application site, which was a major challenge of the delivery of growth factors in
a soluble form as a bolus injection or infusion in the systemic circulation or tissue of interest
[42-46]. Moreover, controlled delivery of FGF9 from PEA electrospun fibers provides
predictable release kinetics of the bioactive agent, which can boost its stability, allow its
sustained release in a biologically active form and provide a more efficient means of
application at the site of interest [21].
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Conclusion
In this chapter, electrospun PEA fibrous mats as a controlled delivery vehicle for FGF2
and FGF9 for potential therapeutic angiogenesis application, using two in vivo models, the
CAM model (as a screening platform) and the ischemic hindlimb mouse model (as a
pathological preclinical model) were evaluated. Localized angiogenesis was observed at
the interface between the FGF-loaded fibrous mat and the CAM surface and there was a
significant enhancement in the quality of vasculature in terms of increased amount of
perfused blood as detected from the 3D power Doppler vascular quantification metrics
(vascularization and vascularization flow indices) of the regions of interest of the CAM
underneath the FGF-loaded PEA fibrous mats. Moving forward to a more clinicallyrelevant model (the ischemic hindlimb model), the implantation of the FGF9-loaded PEA
fibrous mats on the surface of infarcted TA muscle resulted in an increased mural cellwrapping of local microvessels compared to the unloaded fibers group as demonstrated by
the H&E and double immunofluorescent staining. Taken together, FGF-loaded PEA
electrospun fibers can have promising applications in therapeutic angiogenesis for
treatment of ischemic vascular diseases and pre-vascularized tissue engineering.
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Chapter 6
6

General Discussion and Conclusions

Overview: This chapter provides a summary of the research work and discusses the
strengths and limitations of this work. Overall significance of the research work is
highlighted and future directions are recommended.

Summary
In therapeutic angiogenesis, the use of recombinant protein growth factors is a preferred
therapeutic strategy compared with gene therapy, as it potentially offers a more
straightforward treatment [1]. Angiogenic growth factors have been delivered either by
bolus injection or infusion into the systemic circulation or the tissues of interest. However,
the short half-life of these proteins results in a low local availability at the site of interest
that represents the major challenge for angiogenic protein therapy [2]. One approach to
overcome such limitation is the localized and sustained delivery of growth factors at the
desired site from polymer-based delivery systems [3, 4].
Hence, the focus of this research was to develop a controlled delivery system for the
sustained release of angiogenic growth factors over a period of weeks to months in order
to mimic the normal multifaceted angiogenic process and to exogenously augment it [5].
To that end, 8-Phe-4, a member of the biodegradable poly(ester amide) (PEA) family was
utilized to fabricate electrospun nanofibers. The rationale for exploring PEAs is that they
combine the favorable properties of both polyesters and polyamides – the tunability in the
degradation rate via the ester groups and mechanical strength via the hydrogen bonding of the
amide groups. The ester and amide linkages promote both hydrolytic and enzymatic
degradation, which should ensure a surface degradation mechanism [6], and this provides

better prediction and control over the release profile. In addition, PEAs with tailored
degradation rates can be synthesized with the careful selection of the monomers. Their

degradation by-products include amino acids, which are found physiologically, limiting
their potential systemic toxicity [7]. Unlike polyesters, PEA degradation results in less
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acidic by-products, avoiding significant pH decrease in the tissues and thus decreased host
immune responses [8].
One or multiple growth factors can be loaded into PEA delivery vehicles, potentially

sustaining their release, enhancing their therapeutic efficacy and accelerating favorable
cell-material interactions. And the ultimate goal is to support the formation of functional
and stable neovasculature. Electrospinnning is a versatile technique that can produce
delivery vehicles with high surface area-to-volume ratio, which can prolong the angiogenic
factor release and overcome difficulties encountered with angiogenic factor incorporation
within conventional delivery systems, such as controlling the release profile and retaining
growth factor bioactivity. Angiogenic growth factors were previously loaded into
electrospun fibers using blending, emulsion and coaxial electrospinning [9-11], or through
heparin immobilization onto electrospun scaffolds [12]. Controlled-release biodegradable
polymeric fibers can serve as a simple, low-cost and efficient alternative for implantable
mini-infusion pumps for the delivery of angiogenic growth factors, without the need of
delivery system removal after depletion of the growth factor.
Although stimulating angiogenesis using angiogenic growth factors is an essential first
step, it might not be a sufficient condition for producing a stable neovasculature. The
absence of mural cell coverage subjects newly formed vessels to regression; however,
nascent vessels are stabilized and become resistant to regression once they are invested
with pericytes [13]. To mimic the complex angiogenesis process, the delivery of more than
one growth factor in a differential and sustained fashion is required in order to pattern
neovessel maturation and to achieve functional vascular formation. Fibroblast growth
factor-9 (FGF9), an arteriogenic growth factor, was recently reported to play a crucial role
in the recruitment of mural cells and the formation of physiologically mature and stable
neovessels [14]. It acts mainly through Sonic Hedgehog signaling, an upstream regulator
of platelet-derived growth factor receptor-β (PDGFRβ) expression [14], and the PDGFBB/PDGFRβ signaling pathway was reported to be pivotal to recruiting mural cells to the
developing vasculature [15]. When FGF9 was infused into ischemic mouse hindlimb, the
resulting microvessels were found to be invested with more vascular smooth muscle cells
than those generated in the absence of FGF-9. In addition, FGF-9 injection had led to
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enhanced regeneration of the skeletal muscle, along with restoration of limb function [14,
16]. Hence, FGF9 sustained delivery could potentially drive muscularization of angiogenic
sprouts and help regenerate functional neovasculature in ischemic vascular disease
patients.
In the current work, a controlled delivery system for the sustained release of FGF9 has
been developed utilizing electrospun PEA fibers fabricated by either blend or emulsion
electrospinning technique. The morphological properties of the FGF-loaded fibers have
been characterized using SEM and TEM. In vitro PEA matrix degradation,
biocompatibility, in vitro FGF9 and FGF2 release kinetics, and bioactivity of the released
growth factor were evaluated. RT-qPCR was employed to evaluate PDGFRβ gene
expression in NIH-3T3 fibroblasts, 10T1/2 cells, and human coronary artery smooth
muscle cells cultured on PEA fibers at different FGF9 concentrations. FGF9-loaded PEA
fibers exhibited controlled release of FGF9 over 28 days with limited burst effect while
preserving the FGF9 bioactivity. Electrospun PEA fibers were found to support the
proliferation of fibroblasts for five days even in serum-depleted medium. Cells cultured on
FGF9-supplemented PEA mats resulted in upregulation of PDGFRβ in concentration and
cell type-dependent manner (Chapter 3).
Subsequently, FGF2 and FGF9 were dual-loaded using a mixed blend and emulsion
electrospinning technique, and exhibited differential and sustained-release from PEA fibers
over 70 days with preserved bioactivity. In vitro angiogenesis assays showed enhanced
endothelial cell (EC) tube formation and directed-migration of smooth muscle cells
(SMCs) to PDGF-BB, and stabilized EC-SMC tube formation. FGF2/FGF9-loaded PEA
fibers did not induce significant inflammatory response in vitro as shown by the low
interleukin-8 mRNA expression of THP-1 human monocytic cell line or in vivo after their
subcutaneous implantation into mice. Histological examination showed that FGF2/FGF9loaded fibers induced cell niche recruitment around the site of implantation. Furthermore,
controlled in vivo delivery of FGF9 to mouse tibialis anterior muscle resulted in a dosedependent expansion of mesenchymal progenitor-like cell layers and ECM deposition
(Chapter 4).
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Lastly, FGF-loaded PEA fibers were evaluated using two in vivo models, the CAM model
as a screening platform and the ischemic hindlimb mouse model as a pathological preclinical model (Chapter 5). The CAM assay coupled with 3D power Doppler vascular
quantification showed localized angiogenic effects at the regions underneath the FGFloaded fibrous mats, which could indicate the assembly of stable microvessels and
increased blood flow in the CAM owing to the controlled release of FGF2 and FGF9.
Moreover, the implantation of the FGF9-loaded PEA fibrous mats on the surface of
infarcted tibialis anterior muscle resulted in an enhanced skeletal muscle regeneration and
increased abundance of mural-wrapped microvessels compared with the unloaded fibers
control group as demonstrated by the histological analysis. At Day 7 post-ischemia, there
was no significant difference in terms of usage of the injured limb for weight bearing,
between the injured limbs treated with FGF9-loaded fibers compared with those treated
with unloaded PEA fibers. Longer time-point studies (28 days) are proposed to evaluate
the effect of controlled delivery of FGF9 on reversing ischemia and restoration of function.

Strengths and Limitations
Firstly, although PEAs have been electrospun previously from alanine and phenylalanine [17,
18], smaller average fiber diameter (~ 250 nm) was achieved with electrospinning of 8-Phe-4,
due to the higher molecular weight of the synthesized polymer by interfacial polymerization,
and subsequent reduction in the concentration of the polymer required for reaching the optimal
viscosity needed for electrospinning. This would impart increased surface area-to-volume
ratio, which facilitates improved drug loading. The solution and processing parameters were
optimized for fabricating defect-free fibers.
Secondly, although model compounds have been previously loaded into PEA ultrafine fibers
[17, 18], this study demonstrated the versatility of PEA electrospun fibers as a controlled
delivery vehicle for different bioactive molecules (bovine serum albumin, FGF2 and FGF9)
with varying molecular weights (from 14 kD to 60 kD), and dual loading of two growth factors
using mixed blend and emulsion electrospinning techniques. Also, the bioactivity of the
released growth factors and their in vitro release kinetics have been investigated. The surface
erosion degradation mechanism of PEA fibers was studied and correlated to the in vitro release
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profile of the growth factors. The in vitro biocompatibility of the developed 3D scaffold have
been assessed and the PEA fibrous scaffolds demonstrated positive interaction with different
types of cells (NIH 3T3 fibroblasts, C3H 10T1/2 cells and human coronary artery smooth
muscle cells (HCASMC)) in terms of attachment, spreading and proliferation.
Another strength of this study is the evaluation of the induced host immune response in vitro
using human monocytes followed by analysis of gene expression of a targeted inflammatory
marker (Interleukin 8), and in vivo by subcutaneous implantation of the fibrous mats in mice.
PEA fibers neither elicited inflammatory responses nor induced scar formation. Although
inflammation is usually associated with a biomaterial implantation in a host and negative
outcomes (e.g., fibrosis and implant rejection) might take place, some inflammatory reactions
can have positive outcomes that can promote biomaterial-tissue integration and regeneration
[19, 20]. Notwithstanding that, severe induced inflammation and host response often preclude
many synthetic biomaterials from growth factor delivery applications [21].
Moreover, the angiogenic capacity of the FGF-loaded PEA fibers have been evaluated through
in vitro angiogenesis assays (Matrigel tube formation and directed migration assays).
Treatment with FGF2/FGF9-loaded PEA fibers showed enhanced tube formation and directed
migration of HCASMC towards a chemotactic agent PDGF-BB, as well as increased
interaction between ECs and SMCs. Also, it was evaluated in vivo using two models; the chick
chorioallantoic membrane (CAM) assay, as a quick screening platform, and the ischemic
hindlimb mouse model as a pathological model. The CAM assay demonstrated a localized
angiogenic effect due to the controlled release of FGF2 and FGF9, and 3D power Doppler
vascular quantification showed improvement in the quality of microvessels in terms of blood
perfusion in the local microenvironment underneath the fibrous mat. In the ischemic hindlimb
mouse model, injured limbs treated with FGF9-loaded PEA mats resulted in an enhanced

regeneration of the ischemic skeletal muscle with reduced inflammation and minimal tissue
necrosis, and increased abundance of mural-covered microvessels.
The CAM model was simple and it provided a better physiological system for in vivo
analysis than the in vitro assays, but it had some limitations in detecting a significant
increase in vascular density of the full CAM vasculature due to its rapid vascular growth
that outpaced the controlled and relatively slow release of FGF2 and FGF9 from the PEA
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fibers. In addition, the released amount of growth factors from the fibers might not have
reached the effective therapeutic dose to induce significant angiogenesis in the full CAM
surface.
The histological analysis of the ischemic hindlimb mouse model showed promising initial
results 10 days after implantation of the FGF9-loaded fibers in terms of enhanced
regeneration of the ischemic skeletal muscle and increased abundance of mural-covered
microvessels. The CatWalk gait analysis for the mice treated with FGF9-loaded fibrous
mats did not show superior restoration of function of the injured limb when compared with
the group treated with unloaded fibers. Detection of significant differences at Day 7 postischemia in terms of functional recovery of the injured limbs might be early. In view of
this, longer time-point studies (28 days) are proposed in order to evaluate the effect of
controlled delivery of FGF9 on reversing ischemia and restoration of function.

Future Directions
This study investigated the utility of electrospun PEA fibers for dual and sustained delivery
of FGF2 and FGF9 for therapeutic angiogenesis application and the data collectively
indicated that they are promising candidates. In order to advance to the level of angiogenic
therapy clinical studies, the aforementioned limitations with the current study, including
rapid vascular growth of the CAM model that outpaced the controlled and slow release of
FGF2 and FGF9 from the PEA fibers and the CatWalk gait analysis for Day 7 postischemia study that was not able to detect superior restoration of injured limb function for
the FGF9-loaded fibers treated mice, have to be addressed. And to that end:


Longer time-point ischemic hindlimb mouse study (28 days) is proposed in order
to evaluate the effect of controlled delivery of FGF9 on reversing ischemia and
restoration of function.



Ischemic hindlimb perfusion can be assessed by laser Doppler perfusion imaging
and a perfusion ratio can determined by dividing the mean perfusion value of the
dorsal side of the ischemic limb by that of the identical region of the non-ischemic
limb of the mouse.
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RT-qPCR analysis can be employed for in vivo samples to evaluate the mRNA
expression of other inflammatory markers, such as interleukin-6 (IL-6), interleukin1 (IL-1), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-gamma),
together with specific immunohistochemical staining of inflammatory cells (such
as CD68, CD163 and F4/80).



Studying the release kinetics and diffusion pattern of FGF9 in vivo from the PEA
fibers to the infarcted muscle and determining the concentration gradient across
different regions of the tibialis anterior muscle from the skin side to the bone side
is recommended, which may provide better understanding about the therapeutic
efficiency of the released FGF9 in vivo.



Deeper in vivo investigation of the signaling pathway via which FGF9 controls the
mural cell-wrapping of microvessels building on the signaling cascade proposed by
Frontini et al. [14], by conducting RT-qPCR and Western blot protein analyses of
selected signaling molecules other than PDGFR-.



The use of alternative ischemic models is also suggested, such as myocardial
infarction models of larger animals (e.g., canine and porcine models), in order to
better mimic the clinical situation of ischemic vascular disease and have a more
comprehensive investigation of the effects of the controlled delivery of FGF9 on
targeting neovessel maturation.

Significance
This study provides a novel strategy of using amino acid-based biodegradable poly(ester
amide)s to fabricate electrospun fibrous scaffolds for sustained-release of single or multiple
angiogenic growth factors, thus providing a means for minimally invasive
revascularisation technique as the next advance in the treatment of ischemic vascular
diseases.
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